[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 8570
1. Pahernik S, Ziegler S, Roos F, Melchior SW, Thüroff JW: Small renal tumors: correlation of clinical and pathological features with tumor size. J Urol; 2007 Aug;178(2):414-7; discussion 416-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small renal tumors: correlation of clinical and pathological features with tumor size.
  • PURPOSE: We analyzed the association between tumor diameter and pathological stage, histological subtype, tumor grade and the incidence of metastases in renal cell carcinoma with a diameter of up to 4 cm (clinical stage T1a).
  • MATERIALS AND METHODS: We analyzed a consecutive series of 663 patients with renal tumors 4 cm or less who underwent surgery at our institution between 1990 and 2006.
  • After excluding 115 patients (17.3%) with benign tumors 548 with renal cell carcinoma were included in the study.
  • Tumor size on preoperative imaging was correlated with pathological stage, tumor grade, histological subtype and incidence of metastases at diagnosis.
  • For data analysis tumors were stratified by tumor diameter into 3 groups, including 2 cm--99 patients with tumors up to 2 cm, 3 cm--234 with tumors between 2.1 and 3.0 cm, and 4 cm--215 with tumors between 3.1 and 4.0 cm in diameter.
  • RESULTS: Median clinical diameter of renal cell carcinoma in the whole series was 2.93 cm (range 0.8 to 4.0).
  • Tumor stage was pT1a, pT1b and pT3 in 84.5%, 8.0% and 7.5% of cases, respectively.
  • Tumor grade was 1 to 3 in 24.5%, 65.0% and 10.6% of cases, respectively.
  • The renal cell carcinoma histological subtype was clear cell carcinoma in 77.9% of patients, papillary carcinoma in 15.3% and chromophobe carcinoma in 6.8%.
  • Advanced tumor stage (pT3) was found in 3.0%, 5.1% and 12.1% of the patients in the 2, 3 and 4 cm groups, respectively (p <0.05).
  • Metastases at diagnosis were found in 3.0%, 2.6% and 6.0% of the patients in the 2, 3 and 4 cm groups, respectively.
  • CONCLUSIONS: Negative prognostic features increase with tumor diameter and they are associated with even small tumors.
  • However, above a tumor size of 3.0 cm there is a sharp increase in the incidence of negative prognostic parameters.
  • New diagnostic tests are warranted to better stratify patients with respect to treatment aggressiveness for small incidental renal tumors.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Diagnostic Imaging. Disease Progression. Female. Humans. Kidney / pathology. Male. Middle Aged. Neoplasm Staging. Nephrectomy. Prognosis. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561161.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Matusan K, Dordevic G, Mozetic V, Lucin K: Expression of osteopontin and CD44 molecule in papillary renal cell tumors. Pathol Oncol Res; 2005;11(2):108-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of osteopontin and CD44 molecule in papillary renal cell tumors.
  • The aim of the study was to analyze the expression of CD44 adhesion molecule and its ligand osteopontin in papillary renal cell tumors, and to assess the possible prognostic significance of CD44 and osteopontin expression in papillary renal cell carcinomas.
  • The expression of the standard and v6 exon containing isoforms of CD44 molecule, as well as of its ligand osteopontin, was immunohistochemically evaluated in 43 papillary renal cell tumors, which included 5 adenomas and 38 carcinomas.
  • In order to assess their prognostic significance, the results obtained in papillary renal cell carcinomas were compared to usual clinicopathological parameters such as tumor size, histological grade, pathological stage, and Ki-67 proliferation index.
  • Normal renal tissue was negative for CD44s and v6 isoforms, while the expression of osteopontin was found in distal tubular epithelial cells in the form of cytoplasmic granular positivity.
  • CD44s and v6 isoforms were upregulated in 22 (58%) and 12 (32%) out of 38 carcinomas, respectively.
  • Among all clinicopathological parameters examined, we only found significant association of CD44s-positive carcinomas with lower pathological stage (p=0.026).
  • Papillary renal cell adenomas were generally negative for CD44s, except for focal positivity found in one sample.
  • The osteopontin protein was detected in all adenomas and all papillary renal cell carcinomas, except one.
  • Our results show constitutive expression of osteopontin in papillary renal tumors, including papillary renal cell adenomas.
  • The upregulation of CD44s and v6 isoforms, although found in a considerable number of papillary renal cell carcinomas, does not appear to have any prognostic value in this type of renal cancer.
  • [MeSH-major] Antigens, CD44 / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Papillary / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism. Sialoglycoproteins / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Female. Humans. Kidney / metabolism. Kidney / pathology. Male. Neoplasm Staging. Osteopontin

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1994 Sep;145(3):610-23 [8080043.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):513-21 [11929952.001]
  • [Cites] Exp Cell Res. 2003 Aug 15;288(2):257-67 [12915117.001]
  • [Cites] Cancer Surv. 1995;24:19-42 [7553660.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Dec;83(23):8819-23 [3024151.001]
  • [Cites] Virchows Arch. 1996 Jul;428(4-5):267-73 [8764936.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):537-44 [9195569.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2320-6 [10590373.001]
  • [Cites] Mol Cell Biol. 1995 Jan;15(1):476-87 [7799957.001]
  • [Cites] Croat Med J. 2004 Dec;45(6):703-8 [15578803.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3417-27 [12067984.001]
  • [Cites] Am J Surg Pathol. 1997 Jun;21(6):621-35 [9199639.001]
  • [Cites] Gene. 1991 Apr;100:163-71 [2055467.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]
  • [Cites] Am J Pathol. 1996 Feb;148(2):453-63 [8579108.001]
  • [Cites] J Urol. 1999 Jun;161(6):1984-7 [10332486.001]
  • [Cites] Genes Chromosomes Cancer. 1991 Jul;3(4):249-55 [1958590.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):992-3 [9307205.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):517-26 [10433944.001]
  • [Cites] Br J Cancer. 2004 May 17;90(10):1877-81 [15138464.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):119-27 [12833464.001]
  • (PMID = 15999156.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin
  •  go-up   go-down


3. Hillman GG, Wang Y, Che M, Raffoul JJ, Yudelev M, Kucuk O, Sarkar FH: Progression of renal cell carcinoma is inhibited by genistein and radiation in an orthotopic model. BMC Cancer; 2007;7:4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression of renal cell carcinoma is inhibited by genistein and radiation in an orthotopic model.
  • BACKGROUND: We have previously reported the potentiation of radiotherapy by the soy isoflavone genistein for prostate cancer using prostate tumor cells in vitro and orthotopic prostate tumor models in vivo.
  • To clarify whether these intriguing adverse effects of genistein are intrinsic to the orthotopic prostate tumor model, or these results could also be recapitulated in another model, we used the orthotopic metastatic KCI-18 renal cell carcinoma (RCC) model established in our laboratory.
  • METHODS: The KCI-18 RCC cell line was generated from a patient with papillary renal cell carcinoma.
  • Following orthotopic renal implantation of KCI-18 RCC cells and serial in vivo kidney passages in nude mice, we have established a reliable and predictable metastatic RCC tumor model.
  • Mice bearing established kidney tumors were treated with genistein combined with kidney tumor irradiation.
  • The effect of the therapy was assessed on the primary tumor and metastases to various organs.
  • RESULTS: In this experimental model, the karyotype and histological characteristics of the human primary tumor are preserved.
  • Tumor cells metastasize from the primary renal tumor to the lungs, liver and mesentery mimicking the progression of RCC in humans.
  • Treatment of established kidney tumors with genistein demonstrated a tendency to stimulate the growth of the primary kidney tumor and increase the incidence of metastasis to the mesentery lining the bowel.
  • In contrast, when given in conjunction with kidney tumor irradiation, genistein significantly inhibited the growth and progression of established kidney tumors.
  • These findings confirm the potentiation of radiotherapy by genistein in the orthotopic RCC model as previously shown in orthotopic models of prostate cancer.
  • CONCLUSION: Our studies in both RCC and prostate tumor models demonstrate that the combination of genistein with primary tumor irradiation is a more effective and safer therapeutic approach as the tumor growth and progression are inhibited both in the primary and metastatic sites.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / radiotherapy. Genistein / pharmacology. Kidney Neoplasms / drug therapy. Kidney Neoplasms / radiotherapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Disease Progression. Female. Humans. Mice. Mice, Nude

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GENISTEIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nutr Cancer. 1999;35(2):130-6 [10693166.001]
  • [Cites] Radiat Res. 2006 Jul;166(1 Pt 1):73-80 [16808622.001]
  • [Cites] Clin Cancer Res. 2001 Feb;7(2):382-90 [11234894.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6777-82 [11559550.001]
  • [Cites] J Nutr. 2002 Mar;132(3):552S-558S [11880592.001]
  • [Cites] Prostate. 2002 Oct 1;53(2):143-53 [12242729.001]
  • [Cites] Prostate. 2003 Feb 15;54(3):169-80 [12518321.001]
  • [Cites] Cancer. 2004 Jan 1;100(1):201-10 [14692041.001]
  • [Cites] Mol Cancer Ther. 2004 Oct;3(10):1271-9 [15486194.001]
  • [Cites] Cancer Res. 1990 Sep 1;50(17):5531-6 [2386958.001]
  • [Cites] Cancer Metastasis Rev. 1990 Sep;9(2):149-65 [2253314.001]
  • [Cites] Am J Pathol. 1992 Feb;140(2):483-95 [1739137.001]
  • [Cites] Urol Res. 1992;20(4):303-6 [1509637.001]
  • [Cites] Lancet. 1993 Nov 13;342(8881):1209-10 [7901532.001]
  • [Cites] Clin Exp Immunol. 1994 Jun;96(3):476-83 [8004818.001]
  • [Cites] J Urol. 1995 Feb;153(2):490-3 [7815631.001]
  • [Cites] Cell Immunol. 1995 Feb;160(2):257-63 [7720087.001]
  • [Cites] J Nutr. 1995 Sep;125(9):2307-15 [7666247.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4311-8 [7671241.001]
  • [Cites] N Engl J Med. 1996 Sep 19;335(12):865-75 [8778606.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):5189-95 [9371523.001]
  • [Cites] Proc Soc Exp Biol Med. 1998 Mar;217(3):358-64 [9492348.001]
  • [Cites] Clin Cancer Res. 1996 Sep;2(9):1543-52 [9816331.001]
  • [Cites] Nutr Cancer. 1998;32(3):123-31 [10050261.001]
  • [Cites] Actas Urol Esp. 1999 Feb;23(2):156-9 [10327681.001]
  • [Cites] J Nutr. 1999 Sep;129(9):1628-35 [10460196.001]
  • [Cites] Med Sci Monit. 2004 Nov;10(11):BR414-9 [15507846.001]
  • [Cites] Urology. 2005 Nov;66(5 Suppl):1-9 [16194700.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] BMC Cancer. 2006;6:107 [16640785.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):136-44 [11205901.001]
  • (PMID = 17212824.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; DH2M523P0H / Genistein
  • [Other-IDs] NLM/ PMC1783858
  •  go-up   go-down


Advertisement
4. Xu ZF, Xu HX, Xie XY, Liu GJ, Zheng YL, Lu MD: Renal cell carcinoma and renal angiomyolipoma: differential diagnosis with real-time contrast-enhanced ultrasonography. J Ultrasound Med; 2010 May;29(5):709-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma and renal angiomyolipoma: differential diagnosis with real-time contrast-enhanced ultrasonography.
  • OBJECTIVE: The purpose of this study was to evaluate the usefulness of contrast-enhanced ultrasonography (CEUS) in differentiating renal cell carcinoma (RCC) from renal angiomyolipoma (RAML).
  • METHODS: One hundred nineteen patients with 126 renal lesions (33 RAMLs and 93 RCCs) who had undergone CEUS were retrospectively studied.
  • The tumor echogenicity, enhancement patterns, and degree of enhancement at different phases were evaluated.
  • RESULTS: On CEUS, the features of wash-out from hyperenhancement or isoenhancement to hypoenhancement over time (observed in 3.0% of RAMLs and 71.0% of RCCs; P < .001), heterogeneous enhancement (observed in 12.1% of RAMLs and 74.2% of RCCs; P < .001), and an enhanced perilesional rim (observed in 3.0% of RAMLs and 79.6% of RCCs; P < .001) achieved significant difference between RCCs and RAMLs.
  • Early wash-out and heterogeneous enhancement or peritumoral rim enhancement yielded the highest diagnostic capability in differentiating RCC from RAML.
  • CONCLUSIONS: The CEUS features of early wash-out, heterogeneous enhancement, and an enhanced peritumoral rim highly suggest RCC, whereas homogeneous enhancement and prolonged enhancement are characteristic manifestations of RAML.
  • Contrast-enhanced ultrasonography is valuable in differentiating RCC from RAML.
  • [MeSH-major] Angiomyolipoma / ultrasonography. Carcinoma, Renal Cell / ultrasonography. Kidney Neoplasms / ultrasonography. Phospholipids. Sulfur Hexafluoride. Ultrasonography / methods
  • [MeSH-minor] Adult. Aged. Computer Systems. Contrast Media. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20427782.001).
  • [ISSN] 1550-9613
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


5. Berdjis N, Hakenberg OW, Leike S, Zastrow S, Manseck A, Oehlschläger S, Wirth MP: Comparison of transperitoneal versus retroperitoneal approach in laparoscopic radical nephrectomy for renal cell carcinoma: a single-center experience of 63 cases. Urol Int; 2006;77(2):166-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of transperitoneal versus retroperitoneal approach in laparoscopic radical nephrectomy for renal cell carcinoma: a single-center experience of 63 cases.
  • BACKGROUND: We report our experience with the retroperitoneal (RP) and transperitoneal (TP) approaches for laparoscopic nephrectomy for clinically localized renal cell carcinoma.
  • METHODS: Sixty-three patients with renal cell carcinoma were treated with laparoscopic nephrectomy, 34 by TP and 29 by RP approach between June 1999 and June 2003.
  • Average age, ASA score, tumor stage and tumor size were similar in both groups.
  • CONCLUSIONS: Although the sample size is small, it appears that the tumor control and surgical time in laparoscopic nephrectomy are not significantly influenced by the approach.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Laparoscopy / methods. Nephrectomy / methods

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16888424.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


6. Medendorp K, Vreede L, van Groningen JJ, Hetterschijt L, Brugmans L, Jansen PA, van den Hurk WH, de Bruijn DR, van Kessel AG: The mitotic arrest deficient protein MAD2B interacts with the clathrin light chain A during mitosis. PLoS One; 2010;5(11):e15128
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although the mitotic arrest deficient protein MAD2B (MAD2L2) is thought to inhibit the anaphase promoting complex (APC) by binding to CDC20 and/or CDH1 (FZR1), its exact role in cell cycle control still remains to be established.
  • A direct interaction was established in mammalian cells via GST pull-down and endogenous co-immunoprecipitation during the G2/M phase of the cell cycle.
  • Upon siRNA-mediated MAD2B depletion, we found that CLTA was no longer concentrated at the mitotic spindle but, instead, diffusely distributed throughout the cell.
  • CONCLUSIONS/SIGNIFICANCE: Previously, we identified MAD2B as an interactor of the renal cell carcinoma (RCC)-associated protein PRCC.
  • In addition, we found that fusion of PRCC with the transcription factor TFE3 in t(X;1)(p11;q21)-positive RCCs results in an impairment of this interaction and a concomitant failure to shuttle MAD2B to the nucleus.
  • Our current data show that MAD2B interacts with CLTA during the G2/M phase of the cell cycle and that depletion of MAD2B leads to a marked increase in the percentage of misaligned chromosomes and a redistribution of CLTA during mitosis.
  • [MeSH-minor] Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / metabolism. Blotting, Western. Cell Cycle Proteins / genetics. Cell Cycle Proteins / metabolism. Cell Line, Tumor. G2 Phase. HEK293 Cells. Humans. Immunoprecipitation. Luminescent Proteins / genetics. Luminescent Proteins / metabolism. Mad2 Proteins. Microscopy, Confocal. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Protein Binding. RNA Interference. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism. Transfection

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 2000;69:699-727 [10966473.001]
  • [Cites] Am J Physiol Cell Physiol. 2000 Aug;279(2):C369-74 [10913003.001]
  • [Cites] Genes Dev. 2001 Jul 15;15(14):1765-70 [11459826.001]
  • [Cites] Hum Mol Genet. 2001 Sep 1;10(18):1995-2011 [11555636.001]
  • [Cites] J Cell Biol. 2001 Sep 17;154(6):1147-60 [11564755.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13808-13 [11717438.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14434-9 [11724960.001]
  • [Cites] J Cell Biol. 2002 Feb 18;156(4):595-602 [11854305.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):109-17 [11905802.001]
  • [Cites] Oncogene. 2003 Aug 14;22(34):5374-8 [12917640.001]
  • [Cites] J Cell Biol. 2003 Sep 15;162(6):991-1001 [12963708.001]
  • [Cites] J Cell Physiol. 2004 Jun;199(3):330-58 [15095281.001]
  • [Cites] Cytogenet Genome Res. 2004;106(1):68-73 [15218244.001]
  • [Cites] Proc Natl Acad Sci U S A. 1976 Apr;73(4):1255-9 [1063406.001]
  • [Cites] Cytometry. 1990;11(7):837-44 [1703067.001]
  • [Cites] Nature. 1993 Mar 25;362(6418):297-8 [8455715.001]
  • [Cites] Hum Mol Genet. 1996 Sep;5(9):1333-8 [8872474.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15294-8 [8986805.001]
  • [Cites] Trends Biochem Sci. 1998 Aug;23(8):284-6 [9757827.001]
  • [Cites] Genomics. 1999 Jun 1;58(2):181-7 [10366450.001]
  • [Cites] J Cell Biol. 1999 Aug 23;146(4):755-64 [10459011.001]
  • [Cites] Curr Biol. 2005 Feb 22;15(4):R122-4 [15723780.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1152-7 [15858577.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2192-201 [15914641.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4357-67 [16618761.001]
  • [Cites] Curr Biol. 2006 Jun 6;16(11):R412-4 [16753553.001]
  • [Cites] Cell Mol Life Sci. 2006 Aug;63(16):1823-32 [16699812.001]
  • [Cites] Cytogenet Genome Res. 2007;118(2-4):157-65 [18000366.001]
  • [Cites] Oncogene. 2008 Jan 24;27(5):653-62 [17667940.001]
  • [Cites] EMBO J. 2008 Jul 9;27(13):1852-62 [18548008.001]
  • [Cites] Exp Cell Res. 2009 Aug 15;315(14):2399-409 [19422821.001]
  • [Cites] PLoS One. 2009;4(9):e7020 [19753112.001]
  • [Cites] Genes Dev. 2001 Jul 15;15(14):1759-64 [11459825.001]
  • (PMID = 21152103.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Cell Cycle Proteins; 0 / Clathrin Light Chains; 0 / Luminescent Proteins; 0 / MAD2L2 protein, human; 0 / Mad2 Proteins; 0 / Neoplasm Proteins; 0 / PRCC protein, human; 0 / Proteins; 0 / Recombinant Fusion Proteins; 0 / TFE3 protein, human
  • [Other-IDs] NLM/ PMC2994903
  •  go-up   go-down


7. Gómez-Ferrer Lozano A, Navarro Antón JA, Sala Aznar A, Mola Arizo MJ, Polo i Peris AC: [Unilocular cystic renal carcinoma]. Actas Urol Esp; 2007 Jul-Aug;31(7):792-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unilocular cystic renal carcinoma].
  • [Transliterated title] Carcinoma quístico unilocular.
  • We report the case of unilocular cystic renal cell carcinoma and its radiological findings.
  • Cystic renal cell carcinomas are among 3 to 7% of kidney cancers and sometimes are difficult to diagnose, as it happened in this case.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17902478.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


8. Chemaly RF, Sharma PS, Youssef S, Gerber D, Hwu P, Hanmod SS, Jiang Y, Hachem RY, Raad II: The efficacy of catheters coated with minocycline and rifampin in the prevention of catheter-related bacteremia in cancer patients receiving high-dose interleukin-2. Int J Infect Dis; 2010 Jul;14(7):e548-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of catheters coated with minocycline and rifampin in the prevention of catheter-related bacteremia in cancer patients receiving high-dose interleukin-2.
  • High-dose interleukin-2 (HDIL-2) has proven to be an effective treatment for metastatic renal cell carcinoma and melanoma.
  • The primary objective of this study was to evaluate the effectiveness of minocycline and rifampin-coated catheters (M/R-C) in reducing CRB in cancer patients on HDIL-2.
  • This was a retrospective study where non-coated catheters (NC-C) and M/R-C were used for the administration of HDIL-2 before and after December 2004, respectively.
  • Data collected included demographics, cancer type, catheter type, antibiotic prophylaxis, and infection rates.
  • A log-rank test showed a trend that the M/R-C group had lower probability of getting CRB than the NC-C group (p=0.06).
  • The use of M/R-C in patients on HDIL-2 therapy for advanced melanoma and renal cell carcinoma may have reduced the risk of CRB to nil.
  • [MeSH-major] Anti-Bacterial Agents / administration & dosage. Bacteremia / prevention & control. Catheters, Indwelling / adverse effects. Minocycline / administration & dosage. Neoplasms / complications. Rifampin / administration & dosage

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. MINOCYCLINE .
  • Hazardous Substances Data Bank. RIFAMPIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20005762.001).
  • [ISSN] 1878-3511
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents; 0 / Interleukin-2; FYY3R43WGO / Minocycline; VJT6J7R4TR / Rifampin
  • [Number-of-references] 39
  •  go-up   go-down


9. Argani P, Netto GJ, Parwani AV: Papillary renal cell carcinoma with low-grade spindle cell foci: a mimic of mucinous tubular and spindle cell carcinoma. Am J Surg Pathol; 2008 Sep;32(9):1353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary renal cell carcinoma with low-grade spindle cell foci: a mimic of mucinous tubular and spindle cell carcinoma.
  • The solid variant of papillary renal cell carcinoma (PRCC) is distinguishable genetically from mucinous tubular and spindle cell carcinoma (MTSC) of the kidney by the presence of trisomy for chromosomes 7 and 17; however, at the morphologic and immunohistochemical levels, these neoplasms overlap significantly.
  • The key morphologic feature distinguishing these two is thought to be the low grade of the spindle cell areas of MTSC; spindle cell areas in PRCC generally signify sarcomatoid change and are high grade.
  • We report 5 cases of PRCC with low-grade spindle cell foci, closely mimicking MTSC.
  • All tumors were predominantly solid, featuring compact areas of low-grade spindle cells lining thin, angulated tubules.
  • These cases further reported morphologic overlap between MTSC and PRCC.
  • Before a diagnosis of metastatic MTSC or MTSC with unusual morphology is rendered, the possibility of PRCC with low-grade spindle cell foci should be considered.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 7 / genetics. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Trisomy


10. Ishak AI, Md Pauzi SH, Masir N, Goh BS: Multiple metastatic deposits in the head and neck region from a renal cell carcinoma. Malays J Med Sci; 2010 Oct;17(4):71-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple metastatic deposits in the head and neck region from a renal cell carcinoma.
  • Metastatic renal cell carcinoma (RCC) presenting with multiple deposits in the head and neck region is unusual.
  • It is not uncommon for a RCC to metastasise to a distant site after years of a tumour-free period, but most of it would be expected to have a single site of deposit.
  • We report a rare case of a patient who had a nephrectomy 10 years earlier for RCC and presented with tumours in the frontal sinus and posterior pharyngeal wall.
  • Radiological imaging and histology confirmed metastatic RCC at both sites.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22135565.001).
  • [ISSN] 2180-4303
  • [Journal-full-title] The Malaysian journal of medical sciences : MJMS
  • [ISO-abbreviation] Malays J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Malaysia
  • [Other-IDs] NLM/ PMC3216188
  • [Keywords] NOTNLM ; cancer of the head and neck / diagnostic imaging / neoplasm metastases / oncology / renal cell carcinoma / signs and symptoms
  •  go-up   go-down


11. Lim SD, Stallcup W, Lefkove B, Govindarajan B, Au KS, Northrup H, Lang D, Fisher DE, Patel A, Amin MB, Arbiser JL: Expression of the neural stem cell markers NG2 and L1 in human angiomyolipoma: are angiomyolipomas neoplasms of stem cells? Mol Med; 2007 Mar-Apr;13(3-4):160-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the neural stem cell markers NG2 and L1 in human angiomyolipoma: are angiomyolipomas neoplasms of stem cells?
  • Angiomyolipomas are benign tumors of the kidney which express phenotypes of smooth muscle, fat, and melanocytes.
  • These tumors appear with increased frequency in the autosomal dominant disorder tuberous sclerosis and are the leading cause of morbidity in adults with tuberous sclerosis.
  • While benign, these tumors are capable of provoking life threatening hemorrhage and replacement of the kidney parenchyma, resulting in renal failure.
  • The histogenesis of these tumors is currently unclear, although currently, we believe these tumors arise from "perivascular epithelioid cells" of which no normal counterpart has been convincingly demonstrated.
  • Recently, stem cell precursors have been recognized that can give rise to smooth muscle and melanocytes.
  • These precursors have been shown to express the neural stem cell marker NG2 and L1.
  • In order to determine whether angiomyolipomas, which exhibit smooth muscle and melanocytic phenotypes, express NG2 and L1, we performed immunocytochemistry on a cell line derived from a human angiomyolipoma, and found that these cells are uniformly positive.
  • Immunohistochemistry of human angiomyolipoma specimens revealed uniform staining of tumor cells, while renal cell carcinomas revealed positivity only of angiogenic vessels.
  • These results support a novel histogenesis of angiomyolipoma as a defect in differentiation of stem cell precursors.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 1982 Dec 1;156(6):1755-66 [7175440.001]
  • [Cites] Dev Biol. 1981 Apr 15;83(1):154-65 [7016634.001]
  • [Cites] Mayo Clin Proc. 1991 Aug;66(8):792-6 [1861550.001]
  • [Cites] Neuron. 1991 Aug;7(2):209-20 [1873027.001]
  • [Cites] Science. 1991 Oct 25;254(5031):571-3 [1658930.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Aug 21;68(2):193-201 [1394967.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1305-15 [8269512.001]
  • [Cites] Genes Dev. 1994 Aug 15;8(16):1875-87 [7958863.001]
  • [Cites] Genes Dev. 1994 Aug 15;8(16):1888-96 [7958864.001]
  • [Cites] Hum Mol Genet. 1994;3 Spec No:1477-80 [7849741.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11279-83 [7479979.001]
  • [Cites] Am J Hum Genet. 1996 Aug;59(2):400-6 [8755927.001]
  • [Cites] J Neurosci Res. 1996 Feb 1;43(3):299-314 [8714519.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15294-8 [8986805.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1639-47 [9403714.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):21-40 [9503504.001]
  • [Cites] Am J Hum Genet. 1998 Apr;62(4):810-5 [9529362.001]
  • [Cites] Cancer Res. 1998 Nov 1;58(21):4766-70 [9809973.001]
  • [Cites] J Cell Sci. 1999 Mar;112 ( Pt 6):905-15 [10036240.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):295-9 [10088548.001]
  • [Cites] Development. 1999 Jun;126(11):2495-503 [10226008.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2869-74 [10383148.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):117-22 [16001072.001]
  • [Cites] J Biol Chem. 2006 Aug 4;281(31):21582-7 [16737956.001]
  • [Cites] J Cell Sci. 1999 Dec;112 ( Pt 24):4739-49 [10574721.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):28625-33 [10889192.001]
  • [Cites] J Clin Invest. 2000 Oct;106(8):963-71 [11032856.001]
  • [Cites] Oncogene. 2001 Jan 4;20(1):48-57 [11244503.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):483-91 [11485907.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1541-54 [11583980.001]
  • [Cites] Dev Dyn. 2001 Oct;222(2):218-27 [11668599.001]
  • [Cites] FASEB J. 2002 Apr;16(6):586-8 [11919162.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):781-6 [12213705.001]
  • [Cites] Neurobiol Dis. 2003 Nov;14(2):279-90 [14572449.001]
  • [Cites] J Urol. 1986 Jun;135(6):1121-4 [3520013.001]
  • (PMID = 17592550.001).
  • [ISSN] 1076-1551
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / P30 AR 42687; United States / NIAMS NIH HHS / AR / R01 AR050727; United States / NIAMS NIH HHS / AR / P30 AR042687; United States / NIAMS NIH HHS / AR / R01AR 47901; United States / NIAMS NIH HHS / AR / R01 AR 050727; United States / NIAMS NIH HHS / AR / R01 AR047901
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Biomarkers, Tumor; 0 / Leukocyte L1 Antigen Complex; 0 / Proteoglycans; 0 / chondroitin sulfate proteoglycan 4
  • [Other-IDs] NLM/ PMC1892760
  •  go-up   go-down


12. Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM, ARCCS Study Investigators: Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer; 2010 Mar 1;116(5):1272-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
  • BACKGROUND: The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval.
  • Safety and efficacy were explored overall and in subgroups of patients including those with no prior therapy, nonclear cell (nonclear cell) RCC, brain metastases, prior bevacizumab treatment, and elderly patients.
  • Sorafenib was approved for RCC 6 months after study initiation, at which time patients with no prior therapy or with nonclear cell RCC could enroll in an extension protocol for continued assessment for a period of 6 months.
  • RESULTS: The most common grade > or =2 drug-related adverse events were hand-foot skin reaction (18%), rash (14%), hypertension (12%), and fatigue (11%).
  • In the 1891 patients evaluable for response, complete response was observed in 1 patient, partial response in 67 patients (4%), and stable disease for at least 8 weeks in 1511 patients (80%).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyridines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Compassionate Use Trials. Disease-Free Survival. Female. Humans. Male. Middle Aged. Niacinamide / analogs & derivatives. North America. Phenylurea Compounds

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20082451.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00111020
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


13. Onishi T, Franco OE, Shibahara T, Arima K, Sugimura Y: Papillary adenocarcinoma of the renal pelvis and ureter producing carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 125. Int J Urol; 2005 Feb;12(2):214-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenocarcinoma of the renal pelvis and ureter producing carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 125.
  • We report a case of advanced renal pelvis and ureter adenocarcinoma producing carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125).
  • A 72-year-old woman was diagnosed with right renal pelvic and ureter tumor with para-aortic lymph node swelling.
  • Biopsy of the ureteral mass revealed papillary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / immunology. Antigens, Neoplasm / metabolism. Kidney Neoplasms / immunology. Ureteral Neoplasms / immunology
  • [MeSH-minor] Aged. Female. Humans. Kidney Pelvis / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15733120.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


14. Peters I, Rehmet K, Wilke N, Kuczyk MA, Hennenlotter J, Eilers T, Machtens S, Jonas U, Serth J: RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Mol Cancer; 2007;6:49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis.
  • BACKGROUND: Epigenetic silencing of the RAS association domain family 1A (RASSF1A) tumor suppressor gene promoter has been demonstrated in renal cell carcinoma (RCC) as a result of promoter hypermethylation.
  • Contradictory results have been reported for RASSF1A methylation in normal kidney, thus it is not clear whether a significant difference between RASSF1A methylation in normal and tumor cells of the kidney exists.
  • Moreover, RASSF1A expression has not been characterized in tumors or normal tissue as yet.
  • RESULTS: Using combined bisulfite restriction analysis (COBRA) we compared RASSF1A methylation in 90 paired tissue samples obtained from primary kidney tumors and corresponding normal tissue.
  • Bisulfite sequence analysis was carried out using both pooled amplicons from the tumor and normal tissue groups and subclones obtained from a single tissue pair.
  • We found significantly increased methylation in tumor samples (mean methylation, 20%) compared to corresponding normal tissues (mean methylation, 11%; P < 0.001).
  • Immunohistochemical analysis revealed a significant reduced expression of RASSF1A in most of the tumor samples.
  • CONCLUSION: Our methylation and expression data support the hypothesis that RASSF1A is involved in early tumorigenesis of renal cell carcinoma.
  • [MeSH-major] DNA Methylation. Kidney Neoplasms / pathology. Promoter Regions, Genetic. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Cell Line. Cell Line, Tumor. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kidney / metabolism. Kidney / pathology. Male. Middle Aged. Sequence Analysis, DNA / methods. Sulfites / chemistry. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 May 1;65(9):3497-508 [15867337.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):867-74 [16557593.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):492-500 [17234756.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):92-8 [15665283.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):315-9 [10888881.001]
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):691-9 [11333291.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7504-9 [11390984.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):6991-5 [11585722.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7277-81 [11585766.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):212-7 [11668500.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):626-33 [12612901.001]
  • [Cites] Oncogene. 2003 Jun 26;22(26):4128-33 [12821947.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6178-86 [14559801.001]
  • [Cites] Clin Immunol. 2003 Oct;109(1):103-8 [14585281.001]
  • [Cites] Nat Genet. 2004 Feb;36(2):117-8 [14752520.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):129-37 [14743218.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3972-9 [15217927.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):805-10 [15375503.001]
  • [Cites] Pathol Res Pract. 1986 May;181(2):125-43 [3737468.001]
  • [Cites] Nature. 1987 Jun 25-Jul 1;327(6124):721-4 [2885753.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2852-5 [8187067.001]
  • [Cites] Nat Genet. 1994 May;7(1):85-90 [7915601.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9700-4 [7937876.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] J Histochem Cytochem. 1997 Nov;45(11):1455-9 [9358847.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Histochem J. 1999 Mar;31(3):195-200 [10421419.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7276-83 [15534102.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7653-9 [16140931.001]
  • (PMID = 17634119.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / Sulfites; 0 / Tumor Suppressor Proteins; OJ9787WBLU / hydrogen sulfite
  • [Other-IDs] NLM/ PMC1939711
  •  go-up   go-down


15. Albqami N, Janetschek G: Indications and contraindications for the use of laparoscopic surgery for renal cell carcinoma. Nat Clin Pract Urol; 2006 Jan;3(1):32-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indications and contraindications for the use of laparoscopic surgery for renal cell carcinoma.
  • Surgery remains the only treatment with a chance of cure for renal cell carcinoma.
  • Laparoscopic radical nephrectomy (LRN) has developed to be a standard treatment for the management of suspected renal malignancy in many centers worldwide, with oncologic efficacy equal to that of open radical nephrectomy.
  • Current indications for LRN include all patients with localized stage T1-2 renal tumors.
  • LRN for stage T3 renal tumors may be technically feasible in individual situations, but cannot be considered standard treatment.
  • Open radical nephrectomy is reserved for advanced renal tumors, according to the surgeon's judgment.
  • Partial nephrectomy is well established and considered to be the standard management for all organ-confined tumors of <or=4 cm in diameter.
  • The scope of partial nephrectomy, however, is expanding, and now includes patients with organ-confined renal tumors of <or=7 cm.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Laparoscopy / contraindications. Nephrectomy / contraindications

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16474492.001).
  • [ISSN] 1743-4270
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 44
  •  go-up   go-down


16. Yoon SH, Kim KH, Choi J, Kim GM, Kim JH, Kim HS, Park YN, Rha SY: Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis. Cancer Res Treat; 2010 Sep;42(3):180-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis.
  • The proper dose and schedule of sunitinib have yet to be established for patients with metastatic renal cell carcinoma (RCC) on hemodialysis.
  • We reviewed two patients with metastatic RCC on hemodialysis who had been treated with sunitinib in Yonsei Cancer Center, Yonsei University College of Medicine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948925.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2953783
  • [Keywords] NOTNLM ; Renal cell carcinoma / Renal dialysis / Sunitinib
  •  go-up   go-down


17. Egberts F, Kahler KC, Livingstone E, Hauschild A: Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results. Onkologie; 2008 Jul;31(7):398-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In advanced metastatic melanoma (AJCC stage IV), the prognosis is still poor, and views differ on the appropriate systemic treatment for these patients.
  • Sorafenib is an oral multikinase inhibitor that targets 2 classes of kinases which are known to be involved in both tumor proliferation and angiogenesis.
  • These kinases include Raf kinases and the vascular endothelial growth factor (VEGF) receptor.
  • The vast majority of clinical data exists for patients with advanced renal cell cancer for which sorafenib has been approved by the FDA and EMEA.
  • Very recently, sorafenib was approved for advanced hepatocellular cancers due to its overall survival improvement.
  • Since B-raf gene mutations have been found in 69% of melanoma cell lines, sorafenib was brought into various phase I/II and phase III trials in metastatic melanoma.


18. Holcakova J, Hernychova L, Bouchal P, Brozkova K, Zaloudik J, Valik D, Nenutil R, Vojtesek B: Identification of alphaB-crystallin, a biomarker of renal cell carcinoma by SELDI-TOF MS. Int J Biol Markers; 2008 Jan-Mar;23(1):48-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of alphaB-crystallin, a biomarker of renal cell carcinoma by SELDI-TOF MS.
  • Spectrometric-based surface-enhanced laser desorption/ionization ProteinChip (SELDI-TOF) facilitates rapid and easy analysis of protein mixtures and is often exploited to define potential diagnostic markers from sera.
  • However, SELDI- TOF is a relatively insensitive technique and unable to detect circulating proteins at low levels even if they are differentially expressed in cancer patients.
  • Therefore, we applied this technology to study tissues from renal cell carcinomas (RCC) in comparison to healthy controls.
  • We found that different biomarkers are identified from tissues than those previously identified in serum, and that serum markers are often not produced by the tumors themselves at detectable levels, reflecting the nonspecific nature of many circulating biomarkers.
  • We detected and characterized áB-crystallin as an overexpressed protein in RCC tissues and showed differential expression by immunohistochemistry.
  • We suggest that SELDI-TOF should be used to screen human cancer tissues to identify potential tissue-specific proteins and simpler and more sensitive techniques can then be applied to determine their validity as biomarkers in biological fluids.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Renal Cell / chemistry. Kidney Neoplasms / chemistry. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods. alpha-Crystallin B Chain / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Immunohistochemistry. Kidney / chemistry. Male. Sensitivity and Specificity. Tissue Distribution

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18409151.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Crystallin B Chain
  •  go-up   go-down


19. Ares Valdés Y, Fragas Valdés R: [Incidental renal cell carcinoma]. Arch Esp Urol; 2005 Jun;58(5):417-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidental renal cell carcinoma].
  • [Transliterated title] Carcinoma de células renales incidental.
  • OBJECTIVES: To report the incidence and management of incidental renal cell carcinoma (RCC).
  • Thirty cases of RCC were analyzed, 6 of which were incidental.
  • Clinical stage was 4 T1 (66.6%), 2 T2 (33.3%).
  • Follow-up ranged between 120 and 60 months and none of the patients had evidence of tumor activity.
  • CONCLUSIONS: The incidence of incidental RCC in our hospital is 20%.
  • Clinical stage was always low and survival is directly related to stage.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Carcinoma, Renal Cell / diagnosis. Incidental Findings. Kidney Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Cuba / epidemiology. Digestive System Diseases / complications. Digestive System Diseases / radiography. Digestive System Diseases / ultrasonography. Female. Follow-Up Studies. Humans. Interferon-alpha / therapeutic use. Intervertebral Disc Displacement / complications. Intervertebral Disc Displacement / radiography. Male. Middle Aged. Nephrectomy / methods. Recombinant Proteins. Remission Induction. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16078783.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  • [Number-of-references] 15
  •  go-up   go-down


20. Bedke J, Hemmerlein B, Perske C, Gross A, Heuser M: Tumor-associated macrophages in clear cell renal cell carcinoma express both gastrin-releasing peptide and its receptor: a possible modulatory role of immune effectors cells. World J Urol; 2010 Jun;28(3):335-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated macrophages in clear cell renal cell carcinoma express both gastrin-releasing peptide and its receptor: a possible modulatory role of immune effectors cells.
  • PURPOSE: Renal cell carcinomas (RCC) frequently express the gastrin-releasing peptide receptor (GRP-R).
  • Gastrin-releasing peptide (GRP) stimulates tumor cell proliferation and neoangiogenesis.
  • Tumor-associated macrophages (TAM) comprise an important cellular component of these tumors.
  • We analyzed the GRP/GRP-R network in clear cell RCC (ccRCC) and non-clear cell RCC (non-ccRCC) with special regard to its expression by macrophages, tumor cells and microvessels.
  • METHODS: Gastrin-releasing peptide and GRP-R expression in 17 ccRCC and 9 non-ccRCC were analyzed by RT-PCR, immunohistochemistry and double immunofluorescence staining.
  • RESULTS: Tumor-associated macrophages expressed GRP and GRP receptor in ccRCC.
  • Tumor cells and microvessels showed low to intermediate GRP-R expression in nearly all cases.
  • In 12 ccRCC tumor epithelia also expressed low levels of GRP.
  • For non-RCC, the expression of GRP and GRP receptor expression pattern was similar.
  • CONCLUSIONS: Tumor-associated macrophages are the main source of GRP in RCC.
  • GRP receptor on TAM, tumor epithelia and microvessels might be a molecular base of a GRP/GRP receptor network, potentially acting as a paracrine/autocrine modulator of TAM recruitment, tumor growth and neoangiogenesis.
  • [MeSH-major] Carcinoma, Renal Cell / immunology. Gastrin-Releasing Peptide / metabolism. Kidney Neoplasms / immunology. Macrophages / metabolism. Receptors, Bombesin / metabolism
  • [MeSH-minor] Aged. Analysis of Variance. Cell Line, Tumor. Cohort Studies. Female. Fluorescent Antibody Technique. Humans. Immunohistochemistry. Male. Middle Aged. Reference Values. Sensitivity and Specificity


21. Wink MH, Lagerveld BW, Laguna MP, de la Rosette JJ, Wijkstra H: Cryotherapy for renal-cell cancer: diagnosis, treatment, and contrast-enhanced ultrasonography for follow-up. J Endourol; 2006 Jul;20(7):456-8; discussion 458-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cryotherapy for renal-cell cancer: diagnosis, treatment, and contrast-enhanced ultrasonography for follow-up.
  • Cryotherapy is a curative treatment option for patients with small (<4 cm) renal-cell cancers.

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16859453.001).
  • [ISSN] 0892-7790
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Hwang TK: Percutaneous nephroscopic surgery. Korean J Urol; 2010 May;51(5):298-307
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With the development of techniques for percutaneous access and equipment to disintegrate calculi, percutaneous nephroscopic surgery is currently used by many urologists and is the procedure of choice for the removal of large renal calculi and the management of diverticula, intrarenal strictures, and urothelial cancer.
  • Although it is more invasive than shock wave lithotripsy and retrograde ureteroscopic surgery, percutaneous nephroscopic surgery has been successfully performed with high efficiency and low morbidity in difficult renal anatomies and patient conditions.
  • These advantages of minimal invasiveness were rapidly perceived and applied to the management of ureteropelvic junction obstruction, calyceal diverticulum, infundibular stenosis, and urothelial cancer.
  • Currently, percutaneous nephroscopic resection of transitional cell carcinoma in the renal calyx can be applied in indicated cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2001 Dec;166(6):2072-80 [11696709.001]
  • [Cites] J Urol. 2001 Oct;166(4):1242-6 [11547050.001]
  • [Cites] Urology. 2002 Apr;59(4):522-5; discussion 525-6 [11927303.001]
  • [Cites] Eur Urol. 2002 Apr;41(4):474-7 [12074821.001]
  • [Cites] J Endourol. 2002 Jun;16(5):281-8 [12184077.001]
  • [Cites] J Urol. 2002 Nov;168(5):2097-102 [12394717.001]
  • [Cites] Curr Opin Urol. 2003 May;13(3):255-60 [12692451.001]
  • [Cites] Urology. 2003 May;61(5):910-4; discussion 914 [12736002.001]
  • [Cites] Urology. 2004 Feb;63(2):230-4 [14972459.001]
  • [Cites] J Endourol. 2004 Feb;18(1):29-32 [15006049.001]
  • [Cites] Urology. 2004 Jul;64(1):16-21; discussion 21 [15245924.001]
  • [Cites] J Endourol. 2004 Oct;18(8):715-22 [15659890.001]
  • [Cites] BJU Int. 2005 Apr;95(6):791-3 [15794784.001]
  • [Cites] Urol Oncol. 2005 Mar-Apr;23(2):114-22 [15869996.001]
  • [Cites] Urology. 2005 Nov;66(5 Suppl):47-51 [16194707.001]
  • [Cites] J Endourol. 2006 Mar;20(3):194-8 [16548728.001]
  • [Cites] Urol Clin North Am. 2007 Aug;34(3):383-95 [17678988.001]
  • [Cites] Urol Clin North Am. 2008 Aug;35(3):365-83, vii [18761193.001]
  • [Cites] Scand J Urol Nephrol. 1976;10(3):257-9 [1006190.001]
  • [Cites] J Urol. 1991 Oct;146(4):961-5 [1895451.001]
  • [Cites] Radiology. 1991 Dec;181(3):871-7 [1947113.001]
  • [Cites] J Urol. 1990 May;143(5):902-4; discussion 904-5 [2329603.001]
  • [Cites] Urol Clin North Am. 1988 Aug;15(3):425-31 [3407033.001]
  • [Cites] Br J Urol. 1986 Jun;58(3):245-9 [3719242.001]
  • [Cites] Semin Urol. 1986 Aug;4(3):161-9 [3749655.001]
  • [Cites] J Urol. 1986 Jan;135(1):26-8 [3941462.001]
  • [Cites] Urology. 1995 Dec;46(6):791-5 [7502417.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 1):604-8 [7861493.001]
  • [Cites] J Urol. 1994 Apr;151(4):852-4 [8126808.001]
  • [Cites] J Urol. 1994 Apr;151(4):934-7 [8126829.001]
  • [Cites] J Urol. 1996 Mar;155(3):882-4 [8583598.001]
  • [Cites] J Urol. 1997 May;157(5):1613-8; discussion 1618-9 [9112488.001]
  • [Cites] J Urol. 1998 Jan;159(1):56-61 [9400436.001]
  • [Cites] Urol Clin North Am. 1998 May;25(2):251-8 [9633579.001]
  • [Cites] J Urol. 1998 Sep;160(3 Pt 1):685-9 [9720521.001]
  • [Cites] J Urol. 1998 Nov;160(5):1635-9 [9783921.001]
  • [Cites] Tech Urol. 1998 Sep;4(3):160-4 [9800900.001]
  • [Cites] J Endourol. 1998 Oct;12(5):403-5 [9847059.001]
  • [Cites] J Endourol. 1999 Apr;13(3):177-80 [10360497.001]
  • [Cites] J Endourol. 1999 May;13(4):289-94 [10405908.001]
  • [Cites] J Urol. 1999 Sep;162(3 Pt 1):670-3 [10458338.001]
  • [Cites] J Endourol. 1999 Sep;13(7):495-8 [10569522.001]
  • [Cites] J Urol. 2000 Jan;163(1):28-32 [10604307.001]
  • [Cites] J Urol. 2000 Apr;163(4):1124-9 [10737480.001]
  • [Cites] Urol Clin North Am. 2000 Nov;27(4):685-93, ix [11098767.001]
  • [Cites] Urol Clin North Am. 2000 Nov;27(4):739-50 [11098771.001]
  • [Cites] J Urol. 2001 Jul;166(1):36; discussion 36-7 [11435817.001]
  • [Cites] J Urol. 2002 Apr;167(4):1616-20 [11912375.001]
  • (PMID = 20495691.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2873882
  • [Keywords] NOTNLM ; Diverticulum / Hydrocalycosis / Percutaneous nephrostomy / Transitional cell carcinoma / Urinary calculi
  •  go-up   go-down


23. Kawahara H, Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y: Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T&gt;C) of BCRP/ABCG2 gene. Cancer Sci; 2010 Jun;101(6):1493-500
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sunitinib malate (Sutent, SU11248) is a small-molecule multitargeted tyrosine kinase inhibitor (TKI) used for the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumors.
  • Some TKIs can overcome multidrug resistance conferred by ATP-binding cassette transporter, P-glycoprotein (P-gp)/ABCB1, multidrug resistance-associated protein 1 (MRP1)/ABCC1, and breast cancer resistance protein (BCRP)/ABCG2.
  • Intriguingly, the F431L-variant BCRP, which is expressed by a germ-line mutant allele 1291T>C, was almost insensitive to both sunitinib- and fumitremorgin C (FTC)-mediated inhibition in a cell proliferation assay.
  • Collectively, this is the first report showing a differential effect of a germ-line variation of the BCRP/ABCG2 gene on the pharmacological interaction between small-molecule TKIs and BCRP.
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. ATP-Binding Cassette, Sub-Family B, Member 1 / physiology. Animals. Azides / metabolism. Drug Resistance, Neoplasm. Estrone / analogs & derivatives. Estrone / pharmacokinetics. Humans. K562 Cells. Mice. Prazosin / analogs & derivatives. Prazosin / metabolism. Vincristine / pharmacokinetics

  • Hazardous Substances Data Bank. PRAZOSIN HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ESTRONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20345483.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / Azides; 0 / Indoles; 0 / Neoplasm Proteins; 0 / Protein Kinase Inhibitors; 0 / Pyrroles; 2DI9HA706A / Estrone; 5J49Q6B70F / Vincristine; 90990-97-9 / azidoprazosin; QTL48N278K / estrone sulfate; V99T50803M / sunitinib; XM03YJ541D / Prazosin
  •  go-up   go-down


24. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC: VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer; 2010 Jan;46(2):439-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The inhibition of the VEGF signalling axis induces downexpression or suppression of nephrin, an important protein for the maintenance of the glomerular slit diaphragm, sometimes leading to nephritic syndrome and/or glomerular thrombotic microangiopathy, the main-associated kidney disease.
  • The incidence of mild and asymptomatic proteinuria ranges from 21% up to 63%, but heavy proteinuria has been reported in up to 6.5% of renal cell carcinoma patients.
  • Although discontinuation of anti-VEGF agent induced significant reduction, persistence of proteinuria is common.
  • Although angiotensinconverting-enzyme inhibitors and/or angiotensin receptor blockers seem to be preferred, no specific recommendation for an antiproteinuric agent can be made in this context because there are no controlled studies addressing the subject.
  • [MeSH-minor] Down-Regulation. Humans. Hypertension / chemically induced. Kidney Diseases / chemically induced. Kidney Glomerulus. Podocytes / metabolism. Signal Transduction

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20006922.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 70
  •  go-up   go-down


25. Miller K, Bergmann L, Albers P, Jäger E, Jakse G, Geschwend JE, Marschner N: [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma]. Aktuelle Urol; 2007 Jul;38(4):328-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
  • Recently, new data have been published on the treatment of metastasized renal cell cancer using targeted therapies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Renal Cell / therapy. Indoles / therapeutic use. Kidney Neoplasms / therapy. Protein Kinase Inhibitors / therapeutic use. Pyridines / therapeutic use. Pyrroles / therapeutic use
  • [MeSH-minor] Controlled Clinical Trials as Topic. Humans. Immunologic Factors / therapeutic use. Immunotherapy. Interferon-alpha / therapeutic use. Kidney / pathology. Meta-Analysis as Topic. Neoplasm Metastasis. Nephrectomy. Niacinamide / analogs & derivatives. Phenylurea Compounds. Prognosis. Time Factors

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17647172.001).
  • [ISSN] 0001-7868
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Consensus Development Conference; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Immunologic Factors; 0 / Indoles; 0 / Interferon-alpha; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Number-of-references] 18
  •  go-up   go-down


26. Reddy S, Wolfgang CL: The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol; 2009 Mar;10(3):287-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Resection of isolated metastatic colorectal cancer, gastrointestinal stromal tumours, neuroendocrine cancers, renal-cell cancer and sarcoma is associated with longer survival or even cure.
  • The strongest evidence in favour of metastasectomy exists for colorectal cancer, in which resection of limited metastatic disease in some patients is associated with 5-year survival rates of more than 50%.(1-3) High incidence of the disease, predictable tumour biology, and development of successful chemotherapies have encouraged metastasectomy.
  • Furthermore, improved safety of complex surgeries over the past several decades has lowered the threshold for more aggressive surgical intervention.
  • Most literature on metastasectomy pertains to the resection of disease involving the liver, lung, and brain.
  • However, metastasectomy has been described for almost every organ system, including the pancreas.
  • In this Review, we discuss resection of isolated cancer metastases to the pancreas.
  • [MeSH-minor] Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Humans. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Patient Selection. Sarcoma / pathology. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19261257.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 59
  •  go-up   go-down


27. Arai Y, Nonomura N, Nakai Y, Nishimura K, Oka D, Shiba M, Nakayama M, Takayama H, Mizutani Y, Miki T, Okuyama A: The growth-inhibitory effects of dexamethasone on renal cell carcinoma in vivo and in vitro. Cancer Invest; 2008 Feb;26(1):35-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The growth-inhibitory effects of dexamethasone on renal cell carcinoma in vivo and in vitro.
  • BACKGROUND: Recently, several kinase inhibitors have been reported to exert stronger growth inhibitory effects on metastatic renal cell carcinomas (RCCs) than cytokines such as interferons (IFNs) and interleukin-2 (IL-2).
  • The aim of this study is to analyze the growth-inhibitory effects of DEXamethasone (DEX) on RCC in vivo and in vitro.
  • METHODS: The MTT assay was performed using three RCC cell lines, OUR-10, Caki-1, and NC65.
  • OUR-10 cells were subcutaneously transplanted to the dorsal area of nude mice.
  • The nuclear translocation of glucocorticoid receptor (GR) and NF-kappa B was examined using appropriate antibodies.
  • Concentrations of interleukin-6 (IL-6), IL-8, and vascular endothelial cell growth factor (VEGF) in the conditioned media and cytosol were measured by enzyme-linked immunosorbent assay (ELISA).
  • RESULTS: All three RCC cell lines responded to DEX treatment.
  • Intracellular IL-6, as well as IL-6 in the conditioned medium, decreased in OUR-10 cells following treatment with increasing amounts of DEX.
  • Concentrations of IL-8 and VEGF in the conditioned medium of OUR-10 and NC65 cells also decreased following DEX treatment, with the inhibition of nuclear translocation of NF-kappa B.
  • CONCLUSION: DEX treatment is a candidate for advanced RCC therapy by inhibiting the activation of NF-kappa B and its downstream products such as IL-6, IL-8 and VEGF.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Renal Cell / drug therapy. Cell Proliferation / drug effects. Dexamethasone / therapeutic use. Kidney Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Invest. 2009 Jun;27(5):529-32 [19340657.001]
  • (PMID = 18181043.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Interleukin-6; 0 / Interleukin-8; 0 / NF-kappa B; 0 / Receptors, Glucocorticoid; 0 / Vascular Endothelial Growth Factor A; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


28. Bensalah K, Fleureau J, Rolland D, Rioux-Leclercq N, Senhadji L, Lavastre O, Guillé F, Patard JJ, de Crevoisier R: [Optical spectroscopy: a new approach to assess urological tumors]. Prog Urol; 2010 Jul;20(7):477-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Optical spectroscopy: a new approach to assess urological tumors].
  • The objective of this article is to describe these technologies and detail their potential for assessing urological tumors.
  • MATERIAL AND METHODS: It has been shown that optical spectroscopy can accurately analyse multiple solid tumors.
  • Several publications specifically aimed at assessing prostate cancers, renal carcinomas and urothelial tumors.
  • Optical spectroscopy can differentiate benign (adenoma or inflammation) and malignant (adenocarcinoma) prostatic tissues.
  • It can also distinguish normal bladder tissue from inflammatory or cancerous cells.
  • Regarding renal tumors, spectroscopy can identify normal and tumoral tissue and differentiate benign and malignant tumors.
  • However, reported studies only concentrate on in vitro or ex vivo specimen and the numbers of patients are quite small.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20656268.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] France
  •  go-up   go-down


29. Otsuki H, Ito K, Kosaka T, Mikami H, Yoshii H, Asakuma J, Kaji T, Asano T, Hayakawa M: [Adrenal metastasis of lung adenocarcinoma with unusual sites of lymph node metastasis and concomitant renal cell carcinoma: a case report]. Hinyokika Kiyo; 2007 Dec;53(12):879-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adrenal metastasis of lung adenocarcinoma with unusual sites of lymph node metastasis and concomitant renal cell carcinoma: a case report].
  • Right adrenal tumor was found by computed tomography and he was referred to our hospital.
  • Imaging studies revealed right adrenal tumor (8 cm) with marked swelling of surrounding lymph nodes and synchronous left renal tumor (2 cm) that was weakly enhanced by contrast media.
  • Needle biopsy of the left kidney proved to be clear cell type renal cell carcinoma (RCC) and the preoperative diagnosis was left RCC and right primary adrenal cancer with lymph node metastasis.
  • We performed right adrenalectomy, lymph node dissection and left radical nephrectomy.
  • Pathological findings of right adrenal tumor and lymph nodes were both metastatic adenocarcinoma, which was not consistent with RCC or adrenal-derived carcinoma.
  • Then, we extensively reviewed preoperative radiological examinations and found a small lesion in the left upper lung.
  • According to pathological findings and an elevation of carcinoembryogenic antigen, the adrenal lesion was diagnosed as adrenal metastasis of lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adrenal Gland Neoplasms / secondary. Carcinoma, Renal Cell / complications. Kidney Neoplasms / complications. Lung Neoplasms / pathology. Lymphatic Metastasis / pathology. Neoplasms, Multiple Primary


30. Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf M, Lee R, Roberts JD, Fisher PB, Grant S, Dent P: Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res; 2008 Sep 1;14(17):5385-99
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
  • PURPOSE AND DESIGN: Mechanism(s) by which the multikinase inhibitor sorafenib and the histone deacetylase inhibitor vorinostat interact to kill hepatic, renal, and pancreatic adenocarcinoma cells has been defined.
  • RESULTS: Low doses of sorafenib and vorinostat interacted in vitro in a synergistic fashion to kill hepatic, renal, and pancreatic adenocarcinoma cells in multiple short-term viability (24-96 h) and in long-term colony formation assays.
  • Cell killing was suppressed by inhibition of cathepsin proteases and caspase-8 and, to a lesser extent, by inhibition of caspase-9.
  • However, 24 h after exposure, sorafenib- and vorinostat-treated cells exhibited markedly diminished expression of c-FLIP-s, full-length BID, BCL-2, BCL-XL, MCL-1, XIAP, increased expression of BIM, and increased activation of BAX, BAK, and BAD.
  • Expression of eIF2alpha S51A blocked sorafenib- and vorinostat-induced suppression of c-FLIP-s levels and overexpression of c-FLIP-s abolished lethality.
  • CONCLUSIONS: These data show that combined exposure of epithelial tumor cell types to sorafenib and vorinostat diminishes expression of multiple antiapoptotic proteins and promotes activation of the CD95 extrinsic apoptotic and the lysosomal protease pathways, and that suppression of c-FLIP-s expression represents a critical event in transduction of the proapoptotic signals from CD95 to promote mitochondrial dysfunction and death.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Vorinostat .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):18432-40 [10748079.001]
  • [Cites] J Neurooncol. 2008 Apr;87(2):133-41 [18060600.001]
  • [Cites] Mol Biol Cell. 2001 Sep;12(9):2629-45 [11553704.001]
  • [Cites] J Biol Chem. 2002 Jan 18;277(3):2073-80 [11698395.001]
  • [Cites] J Cell Physiol. 2003 May;195(2):290-7 [12652655.001]
  • [Cites] Mol Cell Biol. 2003 May;23(9):3052-66 [12697808.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):18811-6 [12646560.001]
  • [Cites] Nat Cell Biol. 2003 Jul;5(7):647-54 [12792650.001]
  • [Cites] Curr Opin Pharmacol. 2003 Aug;3(4):344-51 [12901942.001]
  • [Cites] Oncogene. 2003 Sep 1;22(37):5885-96 [12947395.001]
  • [Cites] Cancer Biol Ther. 2003 Sep-Oct;2(5):544-51 [14614324.001]
  • [Cites] J Biol Chem. 2004 Feb 13;279(7):5821-8 [14660582.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2205-7 [15073093.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5301-10 [15289336.001]
  • [Cites] Mol Pharmacol. 2004 Oct;66(4):956-63 [15235103.001]
  • [Cites] J Biol Chem. 1997 Jul 11;272(28):17795-801 [9211933.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1319-31 [9782009.001]
  • [Cites] Mol Cancer Ther. 2004 Dec;3(12):1513-24 [15634644.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Biol Chem. 2005 Apr 29;280(17):17196-202 [15710602.001]
  • [Cites] Cancer Lett. 2005 Jul 28;225(2):199-206 [15978324.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6382-9 [16144943.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35217-27 [16109713.001]
  • [Cites] Clin Genitourin Cancer. 2005 Dec;4(3):167-74 [16425993.001]
  • [Cites] Drugs Today (Barc). 2005 Dec;41(12):773-84 [16474853.001]
  • [Cites] Expert Opin Pharmacother. 2006 Mar;7(4):453-61 [16503817.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8858-69 [16951203.001]
  • [Cites] Birth Defects Res B Dev Reprod Toxicol. 2007 Feb;80(1):57-68 [17294457.001]
  • [Cites] Mol Cancer Ther. 2007 Feb;6(2):618-32 [17308059.001]
  • [Cites] Mol Cancer Ther. 2007 Feb;6(2):692-702 [17308065.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):789-801 [17363476.001]
  • [Cites] Cancer. 2007 May 15;109(10):2132-41 [17407132.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 May;7(5):617-26 [17492926.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):66-80 [17613437.001]
  • [Cites] Curr Opin Investig Drugs. 2007 Jun;8(6):452-6 [17621874.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4280-90 [17634558.001]
  • [Cites] Mol Cell Biol. 2007 Aug;27(15):5499-513 [17548474.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4934-42 [17652623.001]
  • [Cites] Mol Cancer Ther. 2007 Aug;6(8):2209-19 [17699718.001]
  • [Cites] Mol Pharmacol. 2007 Sep;72(3):704-14 [17578896.001]
  • [Cites] Mol Pharmacol. 2007 Sep;72(3):788-95 [17595328.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9490-500 [17909059.001]
  • [Cites] Mol Cancer Ther. 2007 Nov;6(11):2967-75 [18025281.001]
  • [Cites] Oncology. 2007;72 Suppl 1:30-44 [18087180.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3101-12 [18065490.001]
  • [Cites] Mol Cancer Ther. 2008 Feb;7(2):314-29 [18281516.001]
  • [Cites] Mol Pharmacol. 2008 Apr;73(4):1168-84 [18182481.001]
  • [Cites] Exp Cell Res. 2001 May 1;265(2):195-202 [11302684.001]
  • (PMID = 18765530.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108520; United States / NCI NIH HHS / CA / R01-CA77141; United States / NCI NIH HHS / CA / P01-CA104177; United States / NCI NIH HHS / CA / R01-CA108520; United States / NIDDK NIH HHS / DK / R01 DK052825-09; United States / NCI NIH HHS / CA / CA104177-030002; United States / NCI NIH HHS / CA / R01-CA63753; United States / NCI NIH HHS / CA / R01 CA063753; United States / NIDDK NIH HHS / DK / R01-DK52825; United States / NCI NIH HHS / CA / CA108520-03; United States / NCI NIH HHS / CA / P01 CA104177-030002; United States / NIDDK NIH HHS / DK / DK052825-09; United States / NCI NIH HHS / CA / P01 CA104177; United States / NIDDK NIH HHS / DK / R01 DK052825; United States / NCI NIH HHS / CA / R01 CA108520-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Benzenesulfonates; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / Hydroxamic Acids; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 58IFB293JI / vorinostat; 9ZOQ3TZI87 / sorafenib
  • [Other-IDs] NLM/ NIHMS55581; NLM/ PMC2561272
  •  go-up   go-down


31. Park JW, Jo MK, Lee HM: Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int; 2009 Mar;103(5):615-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
  • OBJECTIVES: To evaluate the role of (18)F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)/computed tomography (CT) for the surveillance of patients with renal cell carcinoma (RCC) who have a high risk of local recurrence or distant metastasis, by comparing the results with those of conventional imaging methods.
  • PATIENTS AND METHODS: Sixty-three patients with RCC had conventional imaging studies and FDG PET/CT during the follow-up after surgical treatment.
  • The difference in the accuracy of FDG PET/CT by nuclear grade and histological subtype of tumours was also assessed.
  • RESULTS: The FDG PET/CT accurately classified the presence of a recurrence or metastasis in 56 (89%) patients.
  • CONCLUSION: For the surveillance of high-risk RCC, FDG PET/CT had results that were as good as conventional methods and were not influenced by the nuclear grades of cancer cells.
  • In addition, it was possible to examine all organ systems in one procedure, and there was no need for contrast agents, that can damage renal function.
  • [MeSH-major] Carcinoma, Renal Cell. Kidney Neoplasms. Neoplasm Recurrence, Local. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] BJU Int. 2010 Jul;106(1):132-3 [20553479.001]
  • (PMID = 19007371.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


32. McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G: Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res; 2005 Nov 1;11(21):7851-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion.
  • At present, a variety of agents targeting tumor angiogenesis are under clinical investigation as new therapies for patients with cancer.
  • Overexpression of the alpha(v)beta(3) integrin on tumor vasculature has been associated with an aggressive phenotype of several solid tumor types.
  • Murine models have shown that antibodies targeting the alpha(v)beta(3) integrin can affect tumor vasculature and block tumor formation and metastasis.
  • Twenty-five patients with a variety of metastatic solid tumors were treated with MEDI-522 on a weekly basis with doses ranging from 2 to 10 mg/kg/wk.
  • In addition, dynamic computed tomography imaging was done at baseline and at 8 weeks in patients with suitable target lesions amenable to analysis, to potentially identify the effect of MEDI-522 on tumor perfusion.
  • Dynamic computed tomography imaging suggested a possible effect on tumor perfusion with an increase in contrast mean transit time from baseline to the 8-week evaluation with increasing doses of MEDI-522.
  • Three patients with metastatic renal cell cancer experienced prolonged stable disease (34 weeks, >1 and >2 years) on treatment.
  • With this weekly schedule of administration, and in the doses studied, MEDI-522 seems to be without significant toxicity, may have effects on tumor perfusion, and may have clinical activity in renal cell cancer.
  • These findings suggest the MEDI-522 could be further investigated as an antiangiogenic agent for the treatment of cancer.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16278408.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062491; United States / NCRR NIH HHS / RR / M01 RR03186; United States / NCI NIH HHS / CO / N02-CO-124001; United States / NCI NIH HHS / CA / U01 CA62491
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Contrast Media; 0 / Integrin alphaVbeta3
  •  go-up   go-down


33. Kaneko T, Kashibuchi K, Asakage Y, Homma Y: [Epithelioid angiomyolipoma of the kidney]. Nihon Hinyokika Gakkai Zasshi; 2009 Jan;100(1):22-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epithelioid angiomyolipoma of the kidney].
  • A 37-year-old female was referred to our department for a renal mass which was incidentally found during a medical check-up.
  • Computed tomography and magnetic resonance imaging showed a 1.5-cm enhancing mass at the lower pole of the left kidney.
  • An open partial nephrectomy was performed for a pre-operative diagnosis of renal cell carcinoma.
  • Pathological examination revealed sheets of large polygonal epithelioid cells that showed positive immunostaining for HMB-45, which confirmed the diagnosis of an epithelioid angiomyolipoma.
  • The patient remained free of recurrent or metastatic disease at 3 months of follow-up.
  • We present this case and review the literature concerning this unusual disorder.
  • [MeSH-major] Angiomyolipoma / diagnosis. Kidney Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Melanoma-Specific Antigens. Neoplasm Proteins / analysis. Nephrectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19198226.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


34. Cowey CL, Rathmell WK: VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep; 2009 Mar;11(2):94-101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.
  • The therapeutic landscape for renal cell carcinoma (RCC) has changed drastically over the past several years with the emergence of molecularly targeted therapies.
  • Alteration of the von Hippel-Lindau gene (VHL) by mutation, loss of heterozygosity, and promoter methylation has been found to be important to RCC pathogenesis.
  • In this review, we discuss the potential role of VHL mutation as a prognostic and predictive marker for RCC.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Kidney Neoplasms / genetics. Mutation. Von Hippel-Lindau Tumor Suppressor Protein / genetics
  • [MeSH-minor] Biomarkers, Tumor. Humans. Prognosis. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 May 20;399(6733):271-5 [10353251.001]
  • [Cites] Lancet. 2003 Jun 14;361(9374):2059-67 [12814730.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):758s-763s [17255306.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):395-400 [18464292.001]
  • [Cites] Hum Mutat. 1996;8(4):348-57 [8956040.001]
  • [Cites] Oncol Rep. 2005 May;13(5):859-64 [15809750.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3972-9 [15217927.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5215-22 [11431362.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10595-9 [8855223.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4804-7 [7585510.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] J Immunother. 2005 Sep-Oct;28(5):488-95 [16113605.001]
  • [Cites] Mol Cell Biol. 2007 Aug;27(15):5381-92 [17526729.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1942-8 [10766184.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Oncology. 2005;69 Suppl 3:4-10 [16301830.001]
  • [Cites] Genes Chromosomes Cancer. 2002 May;34(1):58-68 [11921283.001]
  • [Cites] Semin Urol Oncol. 2001 May;19(2):148-54 [11354535.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jul;22(3):200-9 [9624531.001]
  • [Cites] Nat Genet. 1994 May;7(1):85-90 [7915601.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] Science. 1993 May 28;260(5112):1317-20 [8493574.001]
  • [Cites] Hum Mol Genet. 1994 Dec;3(12):2169-73 [7881415.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2530-40 [10561319.001]
  • [Cites] PLoS One. 2008;3(11):e3801 [19030229.001]
  • [Cites] J Pathol. 2002 Feb;196 (2):186-93 [11793370.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9700-4 [7937876.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):680s-684s [17255293.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2666-76 [18160686.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] J Urol. 2008 Sep;180(3):860-5; discussion 865-6 [18635227.001]
  • [Cites] Nat Med. 1995 Aug;1(8):822-6 [7585187.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1569-75 [12381710.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14 (15):4726-34 [18676741.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12436-41 [10535940.001]
  • [Cites] J Urol. 2000 Feb;163(2):408-17 [10647643.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] BJU Int. 2006 Oct;98 (4):756-62 [16827904.001]
  • [Cites] Expert Opin Drug Discov. 2008 Mar;3(3):311-327 [20648240.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2852-5 [8187067.001]
  • [Cites] Eur Urol. 2006 Jun;49(6):1051-7 [16387411.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14 (3):782-7 [18245539.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10 (7):763-7 [11257110.001]
  • (PMID = 19216840.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA121781; United States / NCI NIH HHS / CA / R01 CA121781-04
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; EC 2.3.2.27 / Von Hippel-Lindau Tumor Suppressor Protein
  • [Number-of-references] 46
  • [Other-IDs] NLM/ NIHMS202240; NLM/ PMC2873025
  •  go-up   go-down


35. Rini BI: Update on the use of mTOR inhibitors in renal cell carcinoma. Clin Adv Hematol Oncol; 2008 Oct;6(10):722-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the use of mTOR inhibitors in renal cell carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Protein Kinases / chemistry

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18997660.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Interview
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases
  •  go-up   go-down


36. Velayos Jiménez B, Beltrán de Heredia J, del Olmo L, García Castaño J, Fernández L, González JM: [Persistent intestinal bleeding secondary to pancreatic metastasis from renal cell carcinoma]. Rev Esp Enferm Dig; 2006 Mar;98(3):222-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Persistent intestinal bleeding secondary to pancreatic metastasis from renal cell carcinoma].
  • [Transliterated title] Hemorragia digestiva incohercible por metástasis pancreática de cáncer renal.
  • [MeSH-major] Carcinoma, Renal Cell / complications. Carcinoma, Renal Cell / secondary. Gastrointestinal Hemorrhage / etiology. Kidney Neoplasms / pathology. Pancreatic Neoplasms / complications. Pancreatic Neoplasms / secondary


37. Batchelor RJ, Yung A, Merchant W, Goodfield MJ: Pityriasis rubra pilaris as the initial presentation of renal cell carcinoma? Clin Exp Dermatol; 2005 Jul;30(4):442-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pityriasis rubra pilaris as the initial presentation of renal cell carcinoma?
  • [MeSH-major] Carcinoma, Renal Cell / complications. Kidney Neoplasms / complications. Paraneoplastic Syndromes / etiology. Pityriasis Rubra Pilaris / etiology


38. Gira FA, Barbieri A, Fellegara G, Zompatori M, Corradi D: Dedifferentiated chromophobe renal cell carcinoma with massive osteosarcoma-like divergent differentiation: a singular entity in the spectrum of retroperitoneal calcifying tumors. Int J Surg Pathol; 2010 Oct;18(5):419-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated chromophobe renal cell carcinoma with massive osteosarcoma-like divergent differentiation: a singular entity in the spectrum of retroperitoneal calcifying tumors.
  • Sarcomatoid change in renal cell carcinoma is the result of the dedifferentiation of the "parent" tumor into a high-grade malignancy characterized by sarcoma-like features and associated with an accelerated clinical course and poorer prognosis.
  • Any of the renal cell carcinoma subtypes can undergo sarcomatoid dedifferentiation, with the chromophobe variant being the most prone.
  • The present report describes the case of a woman affected by a classic chromophobe renal cell carcinoma that developed dedifferentiation accompanied by a very rare osteosarcoma-like divergent differentiation, which constituted about 90% of the entire retroperitoneal mass.
  • In addition to presenting the relevant imaging, histopathological, and immunohistochemical findings, this article briefly discusses the main differential diagnosis of retroperitoneal ossifying/ calcifying masses, which could give rise to diagnostic problems either in small biopsies or at imaging.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Cell Dedifferentiation. Kidney Neoplasms / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Aged. Calcinosis / complications. Calcinosis / pathology. Cell Transformation, Neoplastic. Diagnosis, Differential. Fatal Outcome. Female. Humans. Neoplasms, Multiple Primary. Radionuclide Imaging. Retroperitoneal Neoplasms / diagnosis. Tomography, X-Ray Computed


39. Uegaki M, Kamba T, Ueda M, Okasyo K, Sano T, Masui K, Negoro H, Soda T, Yoshimura K, Kanematsu A, Nakamura E, Nishiyama H, Ito N, Kamoto T, Ogawa O: [Renal artery pseudoaneurysm following retroperitoneal laparoscopic partial nephrectomy]. Hinyokika Kiyo; 2009 Aug;55(8):499-502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal artery pseudoaneurysm following retroperitoneal laparoscopic partial nephrectomy].
  • We report a case of a 59-year-old woman who presented with gross hematuria due to development of a pseudoaneurysm that was diagnosed using Doppler ultrasonography 16 days after retroperitoneoscopic partial nephrectomy for renal cell carcinoma.
  • [MeSH-major] Aneurysm, False / etiology. Laparoscopy. Nephrectomy / methods. Renal Artery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764537.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 12
  •  go-up   go-down


40. Bryant AS, Cerfolio RJ: The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg; 2006 Sep;82(3):1016-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules.
  • A total of 496 patients had a malignant nodule and the median maxSUV was 8.5 (range, 0 to 36).
  • If the maxSUV was between 0 and 2.5 there was a 24% chance the nodule was malignant, if between 2.6 and 4.0 it was 80%, and if 4.1 or greater it was 96%.
  • False negative FDG-PET/CT was from bronchoalveolar carcinoma in 11 patients, carcinoid in 4, and renal cell in 2.
  • Nodal involvement, whether malignant or infectious, was more likely with a pulmonary mass that had a higher maxSUV (8.4 vs 3.8 for nonmalignant lesions, 9.8 vs 4.5 for malignant lesions).
  • There is a 24% chance a suspicious nodule that has a maxSUV of 0 to 2.5 is cancer.
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Adenocarcinoma, Bronchiolo-Alveolar / radionuclide imaging. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Aged. Carcinoid Tumor / pathology. Carcinoid Tumor / radiography. Carcinoid Tumor / radionuclide imaging. Carcinoid Tumor / surgery. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiography. Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Renal Cell / radiography. Carcinoma, Renal Cell / radionuclide imaging. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Diagnosis, Differential. False Negative Reactions. False Positive Reactions. Female. Frozen Sections. Humans. Lung Diseases, Fungal / radiography. Lung Diseases, Fungal / radionuclide imaging. Lymphatic Metastasis. Male. Middle Aged. Thoracic Surgery, Video-Assisted

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928527.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


41. Hoh BL, Velat GJ, Wilmer EN, Hosaka K, Fisher RC, Scott EW: A novel murine elastase saccular aneurysm model for studying bone marrow progenitor-derived cell-mediated processes in aneurysm formation. Neurosurgery; 2010 Mar;66(3):544-50; discussion 550
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel murine elastase saccular aneurysm model for studying bone marrow progenitor-derived cell-mediated processes in aneurysm formation.
  • METHODS: Elastase is applied extravascularly to the right common carotid artery.
  • Aneurysms and control arteries (left common carotid arteries) were harvested at 1 week, 2 weeks, and 3 weeks postinjury (n = 10 for each time point), measured, and stained for elastin content.
  • To demonstrate BMP-derived cell recruitment to the aneurysms, bone marrow from UBC-gfp transgenic mice was transplanted into irradiated C57BL/6 recipients to create C57BL/6.gfp chimeras.
  • Aneurysms and sham vessels were harvested at 3 weeks and examined for BMP-derived cell recruitment.
  • RESULTS: Aneurysms consistently demonstrated significant loss of elastin in the vessel wall and had significantly larger diameters than control vessels (591 +/- 238 microm vs 328 +/- 61 microm; P = .003 for aneurysms 3 weeks postinjury).
  • Aneurysms from C57BL/6.gfp, FVB.gfp, and C57BL/6.DsRed chimeras consistently revealed significant BMP-derived cell recruitment in the aneurysm wall that was not seen in sham-operated vessels nor in control left common carotid arteries.
  • CONCLUSION: We describe a novel murine elastase saccular aneurysm model that replicates the histopathology and BMP-derived cell-mediated processes that will be a valuable instrument for studying the cell-mediated processes in cerebral aneurysm formation.
  • [MeSH-major] Aneurysm / etiology. Aneurysm / pathology. Bone Marrow Cells / pathology. Disease Models, Animal. Pancreatic Elastase / adverse effects
  • [MeSH-minor] Animals. Carotid Artery, Common / pathology. Carotid Artery, Common / surgery. Green Fluorescent Proteins / genetics. Green Fluorescent Proteins / metabolism. Luminescent Proteins / genetics. Luminescent Proteins / metabolism. Mice. Mice, Inbred C57BL. Mice, Transgenic. Stem Cells / metabolism. Stem Cells / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Aneurysms.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1999 Oct;213(1):223-8 [10540666.001]
  • [Cites] Surg Neurol. 2007;68 Suppl 2:S11-6; discussion S16 [17714769.001]
  • [Cites] AJR Am J Roentgenol. 2000 Feb;174(2):349-54 [10658703.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):698-703 [11290481.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Nov-Dec;22(10):1833-7 [11733310.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Feb;23(2):295-8 [11847058.001]
  • [Cites] Stroke. 2002 Jul;33(7):1911-5 [12105374.001]
  • [Cites] J Surg Res. 2002 Aug;106(2):239-45 [12175973.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1567-72 [12377731.001]
  • [Cites] Circ Res. 2003 Oct 17;93(8):783-90 [14500338.001]
  • [Cites] Circ Res. 2003 Nov 14;93(10):980-9 [14525810.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jul;146(7):705-11 [15197614.001]
  • [Cites] Stroke. 2004 Oct;35(10):2287-93 [15322297.001]
  • [Cites] Surg Neurol. 1981 Oct;16(4):291-6 [7302829.001]
  • [Cites] AJNR Am J Neuroradiol. 1989 Mar-Apr;10(2):400-2 [2494860.001]
  • [Cites] Surg Neurol. 1992 Nov;38(5):331-7 [1485208.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 Jul-Aug;14(4):801-3 [8352147.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 May;15(5):938-44 [8059664.001]
  • [Cites] Neuroradiology. 1994 Oct;36(7):547-50 [7845580.001]
  • [Cites] J Neurosurg. 1996 Sep;85(3):488-95 [8751637.001]
  • [Cites] Neurosurgery. 1996 Mar;38(3):523-31; discussion 532 [8837805.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Oct;17(9):1761-6 [8896634.001]
  • [Cites] Neurosurgery. 1997 Sep;41(3):642-66; discussion 646-7 [9310982.001]
  • [Cites] Stroke. 1998 Feb;29(2):478-85; discussion 485-6 [9472893.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 Aug;19(7):1309-14 [9726474.001]
  • [Cites] Neurosurgery. 1998 Sep;43(3):595-600; discussion 600-1 [9733315.001]
  • [Cites] Minim Invasive Neurosurg. 1998 Sep;41(3):129-32 [9802034.001]
  • [Cites] Stroke. 1999 Jul;30(7):1396-401 [10390313.001]
  • [Cites] N Engl J Med. 1954 Jan 21;250(3):104-6 [13119853.001]
  • [Cites] Cardiovasc Pathol. 2004 Nov-Dec;13(6):306-12 [15556776.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):751-7 [16439710.001]
  • [Cites] Neurosurgery. 2006 May;58(5):936-44; discussion 936-44 [16639330.001]
  • [Cites] Neuroradiology. 2006 Aug;48(8):528-32 [16708202.001]
  • [Cites] Eur J Neurol. 2006 Oct;13(10):1098-105 [16987162.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):1069-76; discussion 1076-7 [17016232.001]
  • [Cites] Neurosurgery. 1999 Nov;45(5):1137-46; discussion 1146-7 [10549930.001]
  • (PMID = 20173550.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K08 NS067058; United States / NINDS NIH HHS / NS / K08 NS067058-01; United States / NINDS NIH HHS / NS / K08 NS067058-02
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Luminescent Proteins; 0 / fluorescent protein 583; 147336-22-9 / Green Fluorescent Proteins; EC 3.4.21.36 / Pancreatic Elastase
  • [Other-IDs] NLM/ NIHMS218893; NLM/ PMC2905737
  •  go-up   go-down


42. Jerónimo C: Quantitative methylation profiling of renal tumors and the discovery of a new generation of molecular markers. Future Oncol; 2005 Apr;1(2):197-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative methylation profiling of renal tumors and the discovery of a new generation of molecular markers.
  • Evaluation of: Gonzalgo ML, Yegnasubramanian S, Yan G et al.: Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. Clin.
  • Cancer Res. 10 (21), 7276-7283 (2004).
  • This study identified RASSF1A promoter methylation as a valuable epigenetic marker for renal cancer, eventually indicating more aggressive disease.
  • Overall, 16 gene promoters were surveyed for hypermethylation in a series of 38 renal cell tumors (comprising papillary and clear-cell renal cell carcinoma, and oncocytoma) and paired normal tissue samples.
  • Among the target genes analyzed, RASSF1A emerged as the most frequently methylated in renal tumors and also at higher levels.
  • Statistical analyses showed a significant association between RASSF1A promoter methylation and higher pathological stage, but not with tumor size or nuclear grade.
  • The discriminative power of a quantitative approach allowed for a segregation between renal carcinomas and oncocytomas, using a self-organizing hierarchical neural network.
  • These results hold the promise that epigenetic-based markers might prove clinically useful for the management of patients with renal tumors.
  • Nevertheless, further studies, including larger sets of patients and more diversified renal tumors, as well as benign lesions, are needed to validate these preliminary results.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Biomarkers, Tumor / genetics. Carcinoma, Papillary / genetics. Carcinoma, Renal Cell / genetics. DNA Methylation. Kidney Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16555990.001).
  • [ISSN] 1479-6694
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


43. Hutson TE, Figlin RA: Evolving role of novel targeted agents in renal cell carcinoma. Oncology (Williston Park); 2007 Sep;21(10):1175-80; discussion 1184, 1187, 1190
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolving role of novel targeted agents in renal cell carcinoma.
  • The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically over the past few years.
  • An improved understanding of the biology of RCC has resulted in the development of novel targeted therapeutic agents that have altered the natural history of this disease.
  • Recently reported and ongoing clinical trials will help further define the role of these agents as therapy for metastatic RCC.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / therapy. Kidney Neoplasms / therapy. Neovascularization, Pathologic / drug therapy. Protein Kinase Inhibitors / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Bevacizumab. Clinical Trials as Topic. Disease-Free Survival. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / antagonists & inhibitors. Hypoxia-Inducible Factor 1, alpha Subunit / drug effects. Immunologic Factors / therapeutic use. Immunosuppressive Agents / therapeutic use. Interleukin-2 / therapeutic use. Protein Kinases. Signal Transduction / drug effects. TOR Serine-Threonine Kinases. Treatment Outcome. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vascular Endothelial Growth Factor A / drug effects

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17926797.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Immunologic Factors; 0 / Immunosuppressive Agents; 0 / Interleukin-2; 0 / Protein Kinase Inhibitors; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases
  • [Number-of-references] 37
  •  go-up   go-down


44. Kai H, Yamagata K, Usui J, Shimizu Y, Hirayama A, Yoh K, Mase K, Hirayama K, Nagase S, Nagata M, Kawai K, Akaza H, Koyama A: Crescentic glomerulonephritis associated with renal cell carcinoma after cancer immunotherapy. J Nephrol; 2005 Jul-Aug;18(4):436-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crescentic glomerulonephritis associated with renal cell carcinoma after cancer immunotherapy.
  • A 59 year-old woman showed rapidly progressive glomerulonephritis during immunotherapy for metastatic renal cell carcinoma.
  • She received unilateral nephrectomy and cytotoxic T lymphocyte (CTL) therapy for the treatment of retroperitoneal lymph node metastasis of renal cell carcinoma.
  • Her renal biopsy specimen revealed necrotizing and crescentic glomerulonephritis with immune complex deposition.
  • Consequently, for the purpose of avoiding interfering with the CTL therapy, we performed double filtration plasmapheresis (DFPP) monotherapy for removal of immune complexes without using immunosuppressive drugs or prednisolone.
  • After 24 sessions of DFPP, her serum IgG was reduced from 3,942 mg/dL to 2,400 mg/dL, and proteinuria (from 9.0 g/day to 0.9 g/day) and renal function (serum creatinine; from 5.6 mg/dL to 2.2 mg/dL) also improved.
  • The autopsy sample of the kidney showed that most of the glomeruli were obsolescent, but immunoglobulin depositions were reduced and necrotizing lesions were diminished.
  • In the patients with RPGN associated with renal cell carcinoma, renal functional recovery has not been observed upon immunosuppressive treatment.
  • We also discuss previous reports of RPGN associated with renal cell carcinoma, or RPGN after cancer immunotherapy.
  • [MeSH-major] Carcinoma, Renal Cell / drug therapy. Glomerulonephritis / chemically induced. Immunologic Factors / adverse effects. Interferon-alpha / adverse effects. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Biopsy. Disease Progression. Fatal Outcome. Female. Humans. Middle Aged


45. Boehm S, Rothermundt C, Hess D, Joerger M: Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini-review. Gerontology; 2010;56(3):303-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At present, inhibition of tumor angiogenesis is a major focus of anticancer drug development.
  • Bevacizumab, a humanized antibody against VEGF, was the first antiangiogenic agent to be approved for advanced non-small cell lung cancer, breast cancer and colorectal cancer.
  • Sunitinib, a small molecule blocking intracellular VEGF, KIT, Flt3 and PDGF receptors, which regulate angiogenesis and cell growth, is approved for the treatment of advanced renal cell cancer (RCC) and malignant gastrointestinal stromal tumor.
  • Sorafenib, an oral multikinase inhibitor, is approved for the second-line treatment of advanced RCC and upfront treatment of advanced hepatocellular carcinoma.
  • Most common adverse events with sorafenib are dermatologic (hand-foot skin reaction, rash, desquamation), fatigue, diarrhea, nausea, hypothyroidism and hypertension.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel.
  • (PMID = 19940466.001).
  • [ISSN] 1423-0003
  • [Journal-full-title] Gerontology
  • [ISO-abbreviation] Gerontology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Drugs, Investigational
  • [Number-of-references] 40
  •  go-up   go-down


46. Haas NB, Uzzo RG: Targeted therapies for kidney cancer in urologic practice. Urol Oncol; 2007 Sep-Oct;25(5):420-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapies for kidney cancer in urologic practice.
  • Renal cell carcinoma (RCC) is the most lethal of all genitourinary malignancies with nearly half of all patients presenting with locally advanced or metastatic disease.
  • The basis of newly approved, more effective targeted therapies for metastatic RCC are based on a fundamental knowledge of the molecular mechanisms that give rise to RCC.
  • We review the clinical data for targeted therapies in RCC and discuss the pertinent biology, side effects, and targets important to the practicing clinician.
  • [MeSH-major] Adenocarcinoma, Clear Cell / therapy. Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / blood supply. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / blood supply. Kidney Neoplasms / therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Benzenesulfonates / therapeutic use. Bevacizumab. Carcinoma, Papillary / blood supply. Carcinoma, Papillary / mortality. Carcinoma, Papillary / therapy. Clinical Trials as Topic. Disease-Free Survival. Evidence-Based Medicine / methods. Humans. Immunotherapy / methods. Indoles / adverse effects. Indoles / therapeutic use. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / prevention & control. Niacinamide / analogs & derivatives. Phenylurea Compounds. Protein Kinase Inhibitors / therapeutic use. Pyridines / therapeutic use. Pyrroles / adverse effects. Pyrroles / therapeutic use. Survival Rate. Treatment Outcome. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vascular Endothelial Growth Factor A / therapeutic use

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826664.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Pyrroles; 0 / Vascular Endothelial Growth Factor A; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 2S9ZZM9Q9V / Bevacizumab; 9ZOQ3TZI87 / sorafenib
  • [Number-of-references] 93
  •  go-up   go-down


47. Wang AJ, Bhayani SB: Robotic partial nephrectomy versus laparoscopic partial nephrectomy for renal cell carcinoma: single-surgeon analysis of &gt;100 consecutive procedures. Urology; 2009 Feb;73(2):306-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic partial nephrectomy versus laparoscopic partial nephrectomy for renal cell carcinoma: single-surgeon analysis of >100 consecutive procedures.
  • No significant difference was found between the estimated blood loss (136 vs 173 mL), tumor size (2.5 vs 2.4 cm), need for pelvicaliceal repair (56% for both), and positive margin rate (1 vs 1 patient) between RPN and LPN, respectively.
  • CONCLUSIONS: RPN can produce results comparable to LPN but has disadvantages, such as cost and assistant control of the renal hilum.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Laparoscopy. Nephrectomy / methods. Robotics

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19038419.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Zhuang SH, Agrawal M, Edgerly M, Bakke S, Kotz H, Thambi P, Rutt A, Balis FM, Bates S, Fojo T: A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer; 2005 May 1;103(9):1932-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prolonged disease stabilization was observed in patients with mesothelioma, ovarian carcinoma, and renal cell carcinoma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Ixabepilone .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2005 by the American Cancer Society.
  • (PMID = 15800893.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epothilones; K27005NP0A / ixabepilone
  •  go-up   go-down


49. Lawrentschuk N, Poon AM, Foo SS, Putra LG, Murone C, Davis ID, Bolton DM, Scott AM: Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int; 2005 Sep;96(4):540-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography.
  • OBJECTIVE: To assess renal tumours for hypoxic regions using 18F-fluoromisonidazole (18F-FMISO) positron emission tomography (PET), a recognized noninvasive method for detecting hypoxia in tumours, as renal cell carcinoma (RCC) can be potentially cured with nephrectomy but recurrence develops in most patients, who then respond poorly to treatments such as chemotherapy, and hypoxia is known to confer resistance to radiotherapy and chemotherapy in many solid tumours.
  • PATIENTS AND METHODS: In all, 17 patients had 18F-FMISO PET scans before nephrectomy for presumed RCC.
  • Specimens were examined histologically, and immunohistochemistry was used to compare the microvessel density (MVD) as an indicator of angiogenesis in the tumour and normal parenchyma, in 15 patients.
  • Tumour oxygenation was measured invasively in three patients using a polarographic oxygen sensor probe.
  • RESULTS: Of the 15 patients with histological results, 11 had RCC and four had other tumours.
  • Although there was a trend there was no statistically significant (P = 0.14) difference in the maximum standardized uptake value (SUV(max)) when comparing the region of the kidney involved with RCC; the mean (95% confidence interval) SUV(max) in the tumours was 1.3 (0.15), whilst that in the normal contralateral kidney was 1.1 (0.22).
  • The MVD was greater in RCC, at 13.7 (3.1) mean vessels per high-power field than in normal tissue, at 6.9 (1.9).
  • Hypoxia as measured polarographically was detected in three RCCs (median pO2 9.6 mmHg) compared to normal parenchyma at 37.6 mmHg.
  • CONCLUSIONS: Although 18F-FMISO scans showed significant uptake in other solid tumours, there was only mild 18F-FMISO uptake in the present RCCs.
  • The invasive measurements indicated that there was hypoxia in RCC, but the median pO2 did not fall below 9.5 mmHg.
  • Further direct studies of renal tumour oxygenation combined with therapies directed towards hypoxia may allow a better understanding of the relationship between 18F-FMISO results and the biological significance of hypoxia in RCC.
  • [MeSH-major] Anoxia / radionuclide imaging. Carcinoma, Renal Cell / radionuclide imaging. Kidney Neoplasms / radionuclide imaging. Misonidazole / analogs & derivatives. Positron-Emission Tomography. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16104907.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 13551-89-8 / fluoromisonidazole; 8FE7LTN8XE / Misonidazole; S88TT14065 / Oxygen
  •  go-up   go-down


50. Kamai T, Tomosugi N, Abe H, Arai K, Yoshida K: Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. BMC Cancer; 2009;9:270
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma.
  • We investigated whether hepcidin was involved in renal cell carcinoma (RCC).
  • METHODS: We measured serum hepcidin-25 levels in 32 patients by liquid chromatograpy (LC)-mass spectrometry (MS)/MS, and assessed hepcidin mRNA expression in paired tumor and non-tumor tissue samples from the surgical specimens of 53 consecutive patients with RCC by real-time reverse transcription polymerase chain reaction.
  • RESULTS: The serum hepcidin-25 level was higher in patients with metastatic RCC than nonmetastatic RCC (P < 0.0001), and was positively correlated with the serum interleukin-6 and C-reactive protein levels (P < 0.001).
  • Expression of hepcidin mRNA was lower in tumor tissues than in non-tumor tissues (P < 0.0001).
  • The serum hepcidin-25 level was not correlated with the expression of hepcidin mRNA in the corresponding tumor tissue specimens from 32 patients.
  • Hepcidin mRNA expression in tumor tissue was correlated with metastatic potential, but not with histological differentiation or tumor stage.
  • Kaplan-Meier analysis showed that over expression of hepcidin mRNA was related to shorter overall survival in RCC patients.
  • CONCLUSION: Our findings suggest that a high serum hepcidin-25 level may indicate the progression of RCC, and that upregulation of hepcidin mRNA expression in tumor tissue may be related to increased metastatic potential.
  • [MeSH-major] Antimicrobial Cationic Peptides / blood. Carcinoma, Renal Cell / blood. Gene Expression Regulation, Neoplastic. Kidney Neoplasms / blood

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2008 Feb 7;27(7):966-75 [17700530.001]
  • [Cites] BMC Cancer. 2007;7:159 [17697365.001]
  • [Cites] BMC Cancer. 2008;8:167 [18541040.001]
  • [Cites] J Urol. 2008 Aug;180(2):515-9 [18550105.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4292-7 [18689548.001]
  • [Cites] J Urol. 2009 Mar;181(3):1004-12; discussion 1012 [19150550.001]
  • [Cites] Eur Urol. 2009 May;55(5):1145-53 [18930583.001]
  • [Cites] Biochim Biophys Acta. 2009 Dec;1796(2):75-90 [19306912.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2632-41 [12855641.001]
  • [Cites] J Clin Pathol. 2000 May;53(5):388-90 [10889822.001]
  • [Cites] Cell. 2000 Oct 13;103(2):311-20 [11057903.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):289-96 [11773181.001]
  • [Cites] Biochim Biophys Acta. 2002 Oct 2;1603(1):31-46 [12242109.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 2;95(7):498-9 [12671009.001]
  • [Cites] Blood. 2003 Aug 1;102(3):783-8 [12663437.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2163-72 [14634372.001]
  • [Cites] J Clin Invest. 2004 May;113(9):1271-6 [15124018.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Cancer. 1978 Sep;42(3):1330-40 [212175.001]
  • [Cites] J Natl Cancer Inst. 1991 Nov 20;83(22):1668-72 [1749019.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3317-22 [1596890.001]
  • [Cites] Urol Clin North Am. 1993 May;20(2):303-21 [8493752.001]
  • [Cites] Semin Oncol. 1995 Feb;22(1):42-60 [7855619.001]
  • [Cites] N Engl J Med. 1996 Sep 19;335(12):865-75 [8778606.001]
  • [Cites] Curr Probl Cancer. 1997 Jul-Aug;21(4):185-232 [9285186.001]
  • [Cites] Br J Cancer. 1998;77(1):147-52 [9459160.001]
  • [Cites] Cell. 1998 Aug 7;94(3):281-4 [9708729.001]
  • [Cites] N Engl J Med. 1999 Feb 11;340(6):448-54 [9971870.001]
  • [Cites] Science. 2004 Dec 17;306(5704):2090-3 [15514116.001]
  • [Cites] J Endocrinol. 2005 Feb;184(2):361-70 [15684344.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 9;338(1):627-38 [16153592.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1381-7 [16621968.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5601-8 [17158546.001]
  • [Cites] BJU Int. 2007 Jan;99(1):77-80 [16956357.001]
  • [Cites] World J Gastroenterol. 2008 Mar 7;14(9):1339-45 [18322945.001]
  • (PMID = 19656379.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimicrobial Cationic Peptides; 0 / HAMP protein, human; 0 / Hepcidins; 0 / Interleukin-6; 0 / RNA, Messenger; 0 / hepcidin 25, human; 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ PMC2729778
  •  go-up   go-down


51. Cannon GM Jr, Getzenberg RH: Urinary matrix metalloproteinase activity is not significantly altered in patients with renal cell carcinoma. Urology; 2006 Apr;67(4):848-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary matrix metalloproteinase activity is not significantly altered in patients with renal cell carcinoma.
  • OBJECTIVES: Matrix metalloproteinases (MMPs) are proteins that degrade the extracellular matrix and have been shown to be elevated in the urine of patients with cancer.
  • One action of MMPs is the degradation of collagen IV that plays a role in tumor invasion and metastasis.
  • This degradation can be measured by a fluorescent microplate activity assay that has been suggested to identify patients with renal cell carcinoma (RCC).
  • Our aim was to confirm the utility of urinary MMP activity as a diagnostic test for RCC.
  • METHODS: Urine samples from 21 patients undergoing nephrectomy for renal masses, as well as from 2 patients undergoing retroperitoneal mass excision for presumed local recurrence, were collected.
  • RESULTS: Of the 21 patients undergoing nephrectomy, 15 had RCC, and both patients undergoing retroperitoneal mass excision had pathologically confirmed RCC recurrence.
  • The mean number of fluorescence units emitted from the urine of patients with RCC was 48,924 units (range 0 to 275,879).
  • CONCLUSIONS: Despite previous evidence, urinary MMP activity was not an adequate test to identify RCC.
  • [MeSH-major] Carcinoma, Renal Cell / enzymology. Carcinoma, Renal Cell / urine. Kidney Neoplasms / enzymology. Kidney Neoplasms / urine. Matrix Metalloproteinases / urine

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566984.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


52. Sonpavde G, Hutson TE: Novel antiangiogenic agents in the treatment of refractory renal cell carcinoma. Clin Genitourin Cancer; 2008 Dec;6 Suppl 1:S29-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel antiangiogenic agents in the treatment of refractory renal cell carcinoma.
  • The approvals of sunitinib, sorafenib, and temsirolimus have dramatically altered the management of renal cell carcinoma.
  • The rapid expansion in the therapeutic armamentarium holds the promise of further enhancing outcomes.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19891127.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  • [Number-of-references] 76
  •  go-up   go-down


53. Hayashi T, Miyagawa Y, Tsujimura A, Nonomura N, Minami M, Okuyama A: A case of renal cell carcinoma with multiple lung metastases refractory to interferon-alpha showing complete remission by interleukin-2 monotherapy. Int J Urol; 2006 Jun;13(6):805-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of renal cell carcinoma with multiple lung metastases refractory to interferon-alpha showing complete remission by interleukin-2 monotherapy.
  • We report a case in which a regimen of interleukin-2 (IL-2) achieved pathologically complete remission against renal cell carcinoma with multiple lung metastases.
  • A 63-year-old man was admitted to the Osaka University Hospital with a right renal tumor and multiple lung metastases.
  • Right radical nephrectomy was performed and the histological diagnosis was clear cell carcinoma, G3 > G2, INFbeta, pT3a, pN0.
  • Resection of this residual lung mass was performed and pathological examination revealed no viable cancer cells.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Renal Cell / therapy. Interleukin-2 / administration & dosage. Kidney Neoplasms / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / radiography. Adenocarcinoma, Clear Cell / therapy. Combined Modality Therapy / methods. Humans. Interferon-alpha / administration & dosage. Middle Aged. Neoplasm Metastasis. Nephrectomy / methods. Remission Induction / methods

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16834666.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-2
  •  go-up   go-down


54. Moujahid M, Zrara I, Touiti D, Daali M: [Renal cell carcinoma with gallbladder metastasis]. Gastroenterol Clin Biol; 2008 Aug-Sep;32(8-9):788-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal cell carcinoma with gallbladder metastasis].
  • [Transliterated title] Métastase vésiculaire d'un cancer du rein.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Gallbladder Neoplasms / secondary. Kidney Neoplasms / pathology


55. Soni SS, Gowrishankar S, Adikey GK, Raman AS: Hereditary leiomyomatosis with renal cell carcinoma. Indian J Dermatol Venereol Leprol; 2008 Jan-Feb;74(1):63-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hereditary leiomyomatosis with renal cell carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Kidney Neoplasms / genetics. Leiomyomatosis / genetics. Skin Neoplasms / genetics

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187832.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  •  go-up   go-down


56. D'Alterio C, Consales C, Polimeno M, Franco R, Cindolo L, Portella L, Cioffi M, Calemma R, Marra L, Claudio L, Perdonà S, Pignata S, Facchini G, Cartenì G, Longo N, Pucci L, Ottaiano A, Costantini S, Castello G, Scala S: Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Curr Cancer Drug Targets; 2010 Nov;10(7):772-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer.
  • CXCR4 is a chemokine receptor implicated in the metastatic process.
  • The CXCR4 ligand, CXCL12, was shown to bind also the CXCR7 receptor, a recently deorphanized chemokine receptor whose signalling pathway and function are still controversial.
  • This study was conducted to determine patients clinic-pathological factors and outcome according to the expressions of CXCR4 and CXCR7 in renal cell carcinoma (RCC).
  • CXCR4 and CXCR7 expression was evaluated in 223 RCC patients through immunohistochemistry; moreover CXCR4 and CXCR7 was detected in 49 others consecutive RCC patients trough RT- PCR.
  • CXCR4 expression was low in 42/223 RCC (18.8%), intermediate in 71/223 (31.9%) and high in 110/223 (49.3%).
  • CXCR7 expression was low in 44/223 RCC patients (19.8%), intermediate in 65/223 (29.1%) and high in 114/223 (51.1%).
  • High CXCR4 and high CXCR7 expression predicted shorter disease free survival.
  • Through RT-PCR, CXCR4 was overexpressed in 36/49 and CXCR7 in 33/49 samples correlating with symptoms at diagnosis and lymph nodes status.
  • So we can hypothesize that CXCR4 and CXCR7, singularly evaluated and in combination, are valuable prognostic factors in RCC patients.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / diagnosis. Kidney Neoplasms / metabolism. Receptors, CXCR / metabolism. Receptors, CXCR4 / metabolism
  • [MeSH-minor] Aged. Aging. Disease-Free Survival. Female. Humans. Immunohistochemistry. Kidney / metabolism. Kidney / pathology. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20578990.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CXCR4 protein, human; 0 / CXCR7 protein, human; 0 / RNA, Messenger; 0 / Receptors, CXCR; 0 / Receptors, CXCR4
  •  go-up   go-down


57. Vasudev NS, Sim S, Cairns DA, Ferguson RE, Craven RA, Stanley A, Cartledge J, Thompson D, Selby PJ, Banks RE: Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma. Br J Cancer; 2009 Oct 6;101(7):1175-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma.
  • BACKGROUND: No circulating markers are routinely used for renal cancer.
  • The objective of this pilot study was to investigate whether conditioned media (CM) from renal cancer cell lines contains potential biomarkers that, when measured in clinical fluids, have diagnostic or prognostic utility.
  • METHODS: Comparative 2D PAGE profiling of CM from renal cell carcinoma (RCC) and normal renal cultures identified cathepsin D that was subsequently validated in urine samples from 239 patients and healthy and benign disease subjects.
  • RESULTS: Urinary cathepsin D was found to be significantly associated with overall (OS) (hazard ratio, HR, 1.33, 95%CI [1.09-1.63], P=0.005) and cancer-specific survival (HR 1.36, 95%CI [1.07-1.74], P=0.013) in RCC patients on univariate analysis.
  • Cathepsin D may be of value as a pre-operative urinary biomarker for RCC, alone or in combination.

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5287-312 [17954709.001]
  • [Cites] J Endourol. 2007 Aug;21(8):819-23 [17867935.001]
  • [Cites] Cancer Treat Rev. 2008 May;34(3):193-205 [18313224.001]
  • [Cites] J Urol. 2008 Jun;179(6):2146-51; discussion 2151 [18423735.001]
  • [Cites] J Transl Med. 2008;6:52 [18796163.001]
  • [Cites] Mol Cell Proteomics. 2008 Oct;7(10):1780-94 [18664563.001]
  • [Cites] Proteomics. 2008 Dec;8(23-24):5074-85 [19003870.001]
  • [Cites] Eur Urol. 2009 Feb;55(2):287-95 [18715700.001]
  • [Cites] Prostate. 2000 Jun 15;44(1):1-7 [10861751.001]
  • [Cites] Biometrics. 2000 Jun;56(2):337-44 [10877287.001]
  • [Cites] AJR Am J Roentgenol. 2000 Sep;175(3):603-8 [10954438.001]
  • [Cites] Electrophoresis. 2000 Nov;21(17):3666-72 [11271485.001]
  • [Cites] Am J Clin Pathol. 2003 Jan;119(1):18-22 [12520693.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1663-71 [12655523.001]
  • [Cites] Arch Pathol Lab Med. 2003 May;127(5):593-6 [12708904.001]
  • [Cites] J Mol Biol. 2004 Jul 16;340(4):783-95 [15223320.001]
  • [Cites] Protein Eng Des Sel. 2004 Apr;17(4):349-56 [15115854.001]
  • [Cites] Biochem J. 1983 Sep 1;213(3):733-40 [6225425.001]
  • [Cites] Cancer Res. 1989 Jul 15;49(14):3904-9 [2736531.001]
  • [Cites] J Urol. 2005 Jan;173(1):48-51 [15592023.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):387-91 [16106245.001]
  • [Cites] Eur Urol. 2005 Sep;48(3):519-26 [16115525.001]
  • [Cites] Proteomics. 2006 May;6(9):2853-64 [16596713.001]
  • [Cites] Cancer Lett. 2006 Jun 18;237(2):167-79 [16046058.001]
  • [Cites] Proteomics. 2006 Jul;6(13):3880-93 [16739133.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6B):4163-70 [17201128.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Urol Int. 2007;79(1):41-3 [17627167.001]
  • [Cites] CMAJ. 2007 Aug 14;177(4):361-8 [17698825.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):571-9 [18385731.001]
  • (PMID = 19789534.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Culture Media, Conditioned; EC 3.4.23.5 / Cathepsin D
  • [Other-IDs] NLM/ PMC2768081
  •  go-up   go-down


58. Butz T, Schmidt HK, Fassbender D, Esdorn H, Wiemer M, Horstkotte D, Faber L: Echo-guided percutaneous coil embolization of a symptomatic massive metastasis of a renal cell carcinoma in the right ventricular outflow tract. Eur J Echocardiogr; 2008 Sep;9(5):725-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Echo-guided percutaneous coil embolization of a symptomatic massive metastasis of a renal cell carcinoma in the right ventricular outflow tract.
  • We present the case of a 41-year-old woman who was admitted to our centre with progressive symptoms of congestive heart failure (NYHA class III) 5 years after a radical nephrectomy for renal cell carcinoma.
  • Magnetic resonance imaging demonstrated a 5 x 3 cm homogeneous intracardial mass causing right ventricular outflow tract obstruction, not accessible to surgical resection.
  • Serial echo-guided, percutaneous coil embolization of the cardial metastasis was performed with Contour SE Microparticles (150-250 or 300-500 microm) after identification of the target region of the metastasis by contrast injection (Levovist) through the balloon catheter into the coronary artery under transoesophageal echocardiographic control prior to induction of the necrosis, corresponding to the technique which has been described for septal ablation in hypertrophic obstructive cardiomyopathy.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Echocardiography. Embolization, Therapeutic / methods. Heart Neoplasms / complications. Heart Neoplasms / therapy. Heart Ventricles / pathology. Kidney Neoplasms / pathology. Ventricular Outflow Obstruction / etiology. Ventricular Outflow Obstruction / therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18490280.001).
  • [ISSN] 1532-2114
  • [Journal-full-title] European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology
  • [ISO-abbreviation] Eur J Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Campus R, Nozza P, Dell'Acqua A, Sementa AR, Gambini C, Dodero P: Eosinophilic chromophobe renal cell carcinoma in a child with hypospadias. Pediatr Blood Cancer; 2008 Feb;50(2):413-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eosinophilic chromophobe renal cell carcinoma in a child with hypospadias.
  • Chromophobe renal cell carcinoma (CRCC) is a distinct variant of renal carcinoma generally affecting adults.
  • This case demonstrates that CRCC can occur in the pediatric patients and can be associated with genital tract anomalies such as Wilms tumor.
  • [MeSH-major] Carcinoma, Renal Cell / complications. Eosinophilia / pathology. Hypospadias / complications. Kidney Neoplasms / complications


60. Yasukawa M, Ochi T, Fujiwara H: Relapse of renal cell carcinoma with disappearance of HLA class I following hTERT peptide vaccination. Ann Oncol; 2010 Oct;21(10):2122-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse of renal cell carcinoma with disappearance of HLA class I following hTERT peptide vaccination.

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20860992.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Histocompatibility Antigens Class I; 0 / Peptide Fragments; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


61. Minervini A, Lanzi F, Carini M: Words of wisdom. Re: enucleation of renal cell carcinoma with ablation of the tumour base. Eur Urol; 2008 Dec;54(6):1442-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Words of wisdom. Re: enucleation of renal cell carcinoma with ablation of the tumour base.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] BJU Int. 2008 Sep;102(6):688-91 [18384627.001]
  • (PMID = 19189438.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


62. Heidemann W, Kasper HU, Gerlach KL: [Mucinous sweat gland carcinoma of a toe with metastasis to the maxilla. A case report]. Pathologe; 2005 May;26(3):221-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mucinous sweat gland carcinoma of a toe with metastasis to the maxilla. A case report].
  • Malignant tumors of the maxilla are rare.
  • In addition to primary tumors metastatic disease has to be considered.
  • Renal cell carcinomas, carcinomas of the breast, lung and adenocarcinomas are constituting the most frequent primary lesions for maxillary metastases.
  • To the best of our knowledge, we present the first case of a mucinous sweat gland carcinoma metastasizing to the maxilla four years after primary diagnosis.
  • Although skin tumors only rarely develop distant metastases, sweat gland carcinomas should be included in the differential diagnosis of tumors metastasizing to the maxilla.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Maxillary Neoplasms / secondary. Sweat Gland Neoplasms / pathology. Toes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Plast Surg. 1999 Sep;43(3):321-3 [10490189.001]
  • [Cites] Arch Dermatol. 1983 Feb;119(2):104-14 [6297408.001]
  • [Cites] Dermatologica. 1988;177(5):295-9 [3243367.001]
  • [Cites] Ann Surg. 1940 Jul;112(1):138-49 [17857618.001]
  • [Cites] J Craniomaxillofac Surg. 1989 Aug;17(6):283-90 [2671045.001]
  • [Cites] Indian J Dent Res. 1997 Oct-Dec;8(4):119-22 [9586526.001]
  • [Cites] Rev Invest Clin. 1996 Jan-Feb;48(1):43-8 [8815485.001]
  • [Cites] Ann Plast Surg. 1998 Nov;41(5):550-4 [9827961.001]
  • [Cites] J Maxillofac Surg. 1982 Nov;10(4):253-8 [6961186.001]
  • [Cites] Acta Pathol Microbiol Scand. 1963;57:361-74 [14064805.001]
  • [Cites] J Laryngol Otol. 1979 Oct;93(10):1011-3 [512463.001]
  • [Cites] Arch Dermatol. 1995 Feb;131(2):211, 214 [7857121.001]
  • [Cites] Proc Finn Dent Soc. 1975 Apr;71(2):58-65 [1144382.001]
  • [Cites] J Dermatol. 1995 Jun;22(6):450-7 [7650246.001]
  • [Cites] J Foot Ankle Surg. 1994 Sep-Oct;33(5):486-91 [7849675.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1974 Jun;37(6):850-7 [4364971.001]
  • [Cites] J Oral Maxillofac Surg. 1982 Dec;40(12):813-8 [6958844.001]
  • [Cites] Dermatol Surg. 2000 Jul;26(7):685-6 [10886280.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):751-7 [8756368.001]
  • [Cites] Am J Surg. 1954 Apr;87(4):496-507 [13138790.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1965 Sep;20:350-62 [14342927.001]
  • (PMID = 15290089.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Manjunath S, Ramachandra C, Murthy V, Murthy PS, Prabhakaran PS, Attili VS: Surgical resection for locally invasive renal cell carcinoma: Is it worthwhile? Indian J Urol; 2007 Jul;23(3):246-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection for locally invasive renal cell carcinoma: Is it worthwhile?
  • BACKGROUND: Many patients with renal cell carcinoma (RCC) present with disease involving the adjacent viscera.
  • We describe our experience with radical nephrectomy for locally invasive RCC over a five-year period.
  • STUDY DESIGN: A retrospective analysis of the records of all patients who had undergone surgery for locally invasive RCC between January 1999 and December 2004 at our institute.
  • MATERIALS AND METHODS: During the study period, 102 patients with RCC underwent surgery at our institute, out of which 18 (17.6%) patients had adjacent organ involvement.
  • RESULTS: Of the 18 patients, two patients had inoperable disease.
  • Fifteen out of the 18 patients succumbed to their disease after a median period of 7.5 months.
  • CONCLUSION: For selected patients with locally invasive RCC, radical nephrectomy with en bloc resection of involved organs may provide the opportunity for long-term survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1997 Apr;64(4):295-8 [9142185.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1995 Jul;86(7):1302-5 [7637249.001]
  • [Cites] J Urol. 1995 Sep;154(3):972-4 [7637104.001]
  • [Cites] J Urol. 1994 Jul;152(1):15-21 [8201647.001]
  • [Cites] J Urol. 1978 Aug;120(2):148-52 [78992.001]
  • [Cites] Urol Clin North Am. 1993 May;20(2):231-46 [8493747.001]
  • [Cites] Urology. 1986 Apr;27(4):291-301 [3962052.001]
  • [Cites] Cancer. 1980 Apr 15;45(7 Suppl):1947-56 [6154520.001]
  • [Cites] Prog Clin Biol Res. 1982;100:497-507 [7145978.001]
  • [Cites] Urol Clin North Am. 1993 May;20(2):263-75 [8493749.001]
  • (PMID = 19718323.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2721599
  • [Keywords] NOTNLM ; Locally invasive / radical nephrectomy / renal cell carcinoma
  •  go-up   go-down


64. Dillenburg W, Poulakis V, Skriapas K, de Vries R, Ferakis N, Witzsch U, Melekos M, Becht E: Retroperitoneoscopic versus open surgical radical nephrectomy for large renal cell carcinoma in clinical stage cT2 or cT3a: quality of life, pain and reconvalescence. Eur Urol; 2006 Feb;49(2):314-22; discussion 322-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneoscopic versus open surgical radical nephrectomy for large renal cell carcinoma in clinical stage cT2 or cT3a: quality of life, pain and reconvalescence.
  • OBJECTIVES: To determine whether retroperitoneoscopic radical nephrectomy for large renal cell carcinoma in stage cT2 or cT3a is a feasible, safe and effective therapy option and if it shows any advantage regarding quality of life in comparison to open procedure.
  • METHODS: 23 patients who underwent RPNx for tumor size greater than 7 cm (group 1) were matched and compared with 25 patients, who underwent ONx (group 2) for tumor with similar size characteristics.
  • CONCLUSIONS: RPNx for large RCC in stage cT2 or cT3a is a safe and efficacious procedure with good short-term outcome results and significantly shorter recovery of QoL variables.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Convalescence. Kidney Neoplasms / surgery. Laparoscopy. Nephrectomy / methods. Pain, Postoperative / etiology. Quality of Life
  • [MeSH-minor] Aged. Analysis of Variance. Body Mass Index. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Pain Measurement. Prospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16377073.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


65. Tsuda K, Kinouchi T, Tanikawa G, Yasuhara Y, Yanagawa M, Kakimoto K, Ono Y, Meguro N, Maeda O, Arisawa J, Usami M: Imaging characteristics of papillary renal cell carcinoma by computed tomography scan and magnetic resonance imaging. Int J Urol; 2005 Sep;12(9):795-800
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging characteristics of papillary renal cell carcinoma by computed tomography scan and magnetic resonance imaging.
  • AIM: To analyse the differences in the patterns between clear and papillary renal cell carcinomas using magnetic resonance imaging (MRI) and dual-phase helical computed tomography (CT).
  • METHODS: We examined seven patients with papillary renal cell carcinoma, and six with clear cell carcinoma.
  • The highest attenuation value of tumors in the corticomedullary phase (CMP) and the excretory phase (EP) was measured using the observer-defined region of interest (ROI).
  • RESULTS: All five tumors except for one with papillary renal cell carcinoma showed homogenous hypointensity, but all six tumors with clear cell carcinoma showed heterogeneous hyperintensity on their T2-weighted images.
  • In the CMP, the mean CT numbers of the papillary renal cell carcinomas were significantly lower than those of the clear cell carcinomas.
  • The mean enhancement of the papillary renal cell carcinomas in the CMP and the EP was significantly lower than that of the clear renal cell carcinomas.
  • The mean CT numbers of the clear cell carcinomas in the CMP were markedly increased from those on the unenhanced CT; those in the EP were decreased gradually.
  • But the mean CT numbers of the papillary renal cell carcinomas in the EP were still slightly more increased than those in the CMP.
  • The enhancement patterns of the papillary renal cell carcinomas in the CMP and the EP were homogenous, but those of the clear cell carcinomas were heterogeneous.
  • CONCLUSIONS: We can speculate the differential diagnosis from clear to papillary renal cell carcinoma using MRI and dual-phase helical CT.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Magnetic Resonance Imaging. Tomography, X-Ray Computed


66. Ahmad A, Modarai B, Saha P, Burnand K: Renal transplantation after excision of the inferior vena cava for residual renal cell carcinoma. Phlebology; 2010 Apr;25(2):100-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal transplantation after excision of the inferior vena cava for residual renal cell carcinoma.
  • A rare case is reported of a 47-year-old patient who had residual tumour left in the stump of his left renal vein and inferior vena cava (IVC) after a left nephrectomy for renal cell carcinoma, having previously had a right nephrectomy for a non-malignant disease.
  • He underwent delayed excision of the residual renal tumour after seven months with a prosthetic graft replacement of the IVC.
  • The patient has subsequently undergone a successful renal transplantation despite a lack of major venous outflow and remains alive and well eight years after initial removal of the tumour from the IVC.


67. Loizzo MR, Tundis R, Menichini F, Saab AM, Statti GA, Menichini F: Antiproliferative effects of essential oils and their major constituents in human renal adenocarcinoma and amelanotic melanoma cells. Cell Prolif; 2008 Dec;41(6):1002-1012
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiproliferative effects of essential oils and their major constituents in human renal adenocarcinoma and amelanotic melanoma cells.
  • OBJECTIVES: The purpose of this study was to evaluate cytotoxic activity of Platycladus orientalis, Prangos asperula and Cupressus sempervirens ssp. pyramidalis essential oils and to identify active components involved in inhibition of population growth of human cancer cell lines.
  • Antiproliferative activity was tested on amelanotic melanoma C32 cells and on renal cell adenocarcinoma cells, using the sulphorhodamine B assay.
  • RESULTS: Cupressus sempervirens ssp. pyramidalis leaf oil exerted the highest cytotoxic activity with an IC(50)value of 104.90 microg/mL against C32, followed by activity of P. orientalis and P. asperula on the renal adenocarcinoma cell line (IC(50) of 121.93 and 139.17 microg/mL, respectively). P. orientalis essential oil was also active against amelanotic melanoma with an IC(50) of 330.04 microg/mL.
  • Three identified terpenes, linalool, beta-caryophyllene and alpha-cedrol, were found to be active on both cell lines tested.
  • This study provided evidence on how cytotoxic activity of the oils is not always related to their major constituents, except for lower activity found in both cell lines for alpha-cedrol.
  • Interestingly, beta-caryophyllene and linalool exhibited comparable IC(50) values to the commercial drug vinblastine on the ACHN cell line.
  • [MeSH-major] Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / drug therapy. Melanoma, Amelanotic / drug therapy. Melanoma, Amelanotic / pathology. Oils, Volatile / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Cell Death / drug effects. Cell Line. Cell Proliferation / drug effects. Cupressus / chemistry. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Humans. Phytotherapy. Plant Oils / chemistry. Plant Oils / pharmacology. Plant Oils / therapeutic use. Terpenes / pharmacology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19040575.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oils, Volatile; 0 / Plant Oils; 0 / Terpenes
  •  go-up   go-down


68. Engwegen JY, Mehra N, Haanen JB, Schellens JH, Voest EE, Beijnen JH: Identification of two new serum protein profiles for renal cell carcinoma. Oncol Rep; 2009 Aug;22(2):401-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of two new serum protein profiles for renal cell carcinoma.
  • Renal cell carcinoma (RCC) is the most lethal urological cancer, and survival greatly depends on early diagnosis.
  • Therefore, reliable, new biomarkers for detection of RCC are required.
  • We assessed serum protein profiles of samples from two institutes with SELDI-TOF MS in duplicate on CM10 chips at pH 6.0 (set 1: 37 RCC + 32 healthy controls (HC), set 2: 20 RCC + 25 HC).
  • Mean peak intensities of detected proteins were compared between RCC and HC with non-parametric testing.
  • We found 15 peaks significantly different (p<0.01) between RCC and HC.
  • Although two serum protein profiles comprising 5 protein peaks were found that could separate RCC from HC, the sensitivity and specificity is not sufficient to recommend large scale use.
  • Upon structural identification and quantitative validation, however, these proteins might prove suitable markers in the follow up of RCC patients.
  • [MeSH-major] Blood Proteins / analysis. Carcinoma, Renal Cell / blood. Kidney Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Biomarkers, Tumor / blood. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19578783.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins
  •  go-up   go-down


69. Mignogna C, Staibano S, Altieri V, De Rosa G, Pannone G, Santoro A, Zamparese R, D'Armiento M, Rocchetti R, Mezza E, Nasti M, Strazzullo V, Montanaro V, Mascolo M, Bufo P: Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis. BMC Cancer; 2006;6:293
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis.
  • BACKGROUND: A large number of renal cancer patients shows poor or partial response to chemotherapy and the mechanisms have not been still understood.
  • Multi-drug resistance is the principal mechanism by which many cancers develop resistance to chemotherapic drugs.
  • We studied MDR-1 expression in selected cases of renal cell carcinoma (RCC), clear cell type, with long-term follow-up, in order to establish its prognostic role and its possible contribution in the choice of post-surgical therapy.
  • METHODS: MDR-1 has been studied by standard LSAB-HRP immunohistochemical technique, in paraffin embedded RCC samples.
  • Protein expression has been compared to clinical and histopathological data and to disease specific survival of RCC patients, by Kaplan-Meier curve and Cox multivariate regression analyses.
  • RESULTS: Two groups of RCCs were obtained by esteeming MDR-1 expression and disease specific survival (obtained with Kaplan-Meier curve and Cox multivariate regression analyses): the first one presents low or absent MDR-1 expression and good survival; the second one is characterized by high MDR-1 expression and significant poor outcome (p < 0.05).
  • Afterwards, we have found disease specific survival, adjusted for stages and independent of therapy: this difference of survival rates was statistically significant (p < 0.05).
  • Stage adjusted disease specific survival rate, according to MDR-1 expression and therapy in patients affected by RCC in early stage (stage I), has revealed that the group of patients with high MDR-1 expression and without adjuvant therapy showed poor survival (p < 0.05).
  • Cox multivariate regression analysis has confirmed that, in our cohort of RCC (clear cell type) patients, the strong association between MDR-1 and worse outcome is independent not only of the adjuvant therapy, but also of the other prognostic parameters (p < 0.05).
  • CONCLUSION: In our opinion, the results of this study well prove the relationship between MDR-1 expression and worse clinical prognosis in RCC, because MDR-1 over-expressing RCCs can be considered a group of tumours with a more aggressive behavior.
  • This finding outlines a possible role of MDR-1 as prognostic factor, dependent and independent of multidrug resistance.
  • These results could be useful to predict cancer evolution and to choose the appropriate treatment: this is another step that can stimulate further promising and interesting investigations on broader study population.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / diagnosis. Kidney Neoplasms / metabolism. P-Glycoprotein / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Biomarkers, Tumor / physiology. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic / physiology. Humans. Male. Middle Aged. Prognosis. Survival Rate / trends

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1983 Jul;130(1):20-3 [6864906.001]
  • [Cites] J Urol. 1969 Mar;101(3):297-301 [5765875.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Nov;84(21):7735-8 [2444983.001]
  • [Cites] J Clin Oncol. 1987 Dec;5(12):1922-7 [3681376.001]
  • [Cites] Cancer. 1988 Apr 15;61(8):1639-51 [3349424.001]
  • [Cites] Eur Urol. 1988;15(3-4):271-6 [3215262.001]
  • [Cites] Semin Oncol. 1989 Feb;16(1 Suppl 1):12-9 [2465574.001]
  • [Cites] Semin Oncol. 1989 Feb;16(1 Suppl 1):3-11 [2645654.001]
  • [Cites] Semin Urol. 1989 Nov;7(4):199-206 [2694257.001]
  • [Cites] J Histochem Cytochem. 1990 Sep;38(9):1277-87 [1974900.001]
  • [Cites] Cancer Res. 1991 May 15;51(10):2720-6 [1673639.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2403-6 [1933777.001]
  • [Cites] Urol Int. 1991;47(4):203-12 [1781104.001]
  • [Cites] J Urol. 1992 Aug;148(2 Pt 1):271-4 [1635115.001]
  • [Cites] Oncology. 1994 Jul-Aug;51(4):309-13 [7911563.001]
  • [Cites] Cancer Res. 1994 Oct 15;54(20):5351-6 [7923164.001]
  • [Cites] Cancer Lett. 1996 Apr 19;102(1-2):7-16 [8603381.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):892-8 [8631030.001]
  • [Cites] Br J Urol. 1997 Jul;80(1):11-7 [9240173.001]
  • [Cites] Nephron. 1997;77(3):284-9 [9375821.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1998 Jul;89(7):647-56 [9739586.001]
  • [Cites] Lancet. 1998 Nov 21;352(9141):1691-6 [9853456.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1999;39:361-98 [10331089.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] BJU Int. 2005 Mar;95 Suppl 2:8-13 [15759349.001]
  • [Cites] J Clin Pharmacol. 2005 Aug;45(8):872-7 [16027397.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):813-4 [16469556.001]
  • [Cites] Biol Pharm Bull. 2006 Jul;29(7):1449-53 [16819187.001]
  • [Cites] J Clin Pathol. 1999 Jun;52(6):450-4 [10562814.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2401-7 [10873092.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8490-4 [10890910.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1065-75 [10964337.001]
  • [Cites] Urol Int. 2001;66(2):78-83 [11223748.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):39359-67 [11483599.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):658-64 [11857297.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):323-30 [11920581.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):121-8 [12017273.001]
  • [Cites] Biol Pharm Bull. 2002 Nov;25(11):1391-400 [12419946.001]
  • [Cites] J Urol. 2003 Mar;169(3):821-7 [12576793.001]
  • [Cites] Clin Pharmacol Ther. 2003 Mar;73(3):223-31 [12621387.001]
  • [Cites] Pharm Res. 2003 Sep;20(9):1394-400 [14567633.001]
  • [Cites] Int J Clin Pract. 2004 Apr;58(4):333-6 [15161115.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):503-8 [4005812.001]
  • (PMID = 17177989.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / P-Glycoprotein
  • [Other-IDs] NLM/ PMC1766933
  •  go-up   go-down


70. Muñoz-Delgado E, Montenegro MF, Campoy FJ, Moral-Naranjo MT, Cabezas-Herrera J, Kovacs G, Vidal CJ: Expression of cholinesterases in human kidney and its variation in renal cell carcinoma types. FEBS J; 2010 Nov;277(21):4519-29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cholinesterases in human kidney and its variation in renal cell carcinoma types.
  • Despite the aberrant expression of cholinesterases in tumours, the question of their possible contribution to tumorigenesis remains unsolved.
  • The identification in kidney of a cholinergic system has paved the way to functional studies, but details on renal cholinesterases are still lacking.
  • To fill the gap and to determine whether cholinesterases are abnormally expressed in renal tumours, paired pieces of normal kidney and renal cell carcinomas (RCCs) were compared for cholinesterase activity and mRNA levels.
  • In studies with papillary RCC (pRCC), conventional RCC, chromophobe RCC, and renal oncocytoma, acetylcholinesterase activity increased in pRCC (3.92 ± 3.01 mU·mg(-1), P = 0.031) and conventional RCC (2.64 ± 1.49 mU·mg(-1), P = 0.047) with respect to their controls (1.52 ± 0.92 and 1.57 ± 0.44 mU·mg(-1)).
  • Glycosylphosphatidylinositol-linked acetylcholinesterase dimers and hydrophilic butyrylcholinesterase tetramers predominated in control and cancerous kidney.
  • Acetylcholinesterase mRNAs with exons E1c and E1e, 3'-alternative T, H and R acetylcholinesterase mRNAs and butyrylcholinesterase mRNA were identified in kidney.
  • The levels of acetylcholinesterase and butyrylcholinesterase mRNAs were nearly 1000-fold lower in human kidney than in colon.
  • Whereas kidney and renal tumours showed comparable levels of acetylcholinesterase mRNA, the content of butyrylcholinesterase mRNA was increased 10-fold in pRCC.
  • The presence of acetylcholinesterase and butyrylcholinesterase mRNAs in kidney supports their synthesis in the organ itself, and the prevalence of glycosylphosphatidylinositol-anchored acetylcholinesterase explains the splicing to acetylcholinesterase-H mRNA.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Cholinesterases / genetics. Kidney / metabolism. Kidney Neoplasms / genetics


71. Kala S, Pantola C, Agarwal A: Metastatic adenoid cystic carcinoma of kidney masquerading as renal cell carcinoma. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):835-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenoid cystic carcinoma of kidney masquerading as renal cell carcinoma.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / secondary. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Kidney Neoplasms / secondary
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Histocytochemistry. Humans. Medical History Taking. Microscopy. Nephrectomy. Radiography, Abdominal. Salivary Gland Neoplasms / diagnosis. Tomography, X-Ray Computed. Ultrasonography


72. Ahn KS, Yong HS, Lee JW, Woo OH, Kang EY: Right circumflex retro-oesophageal aortic arch with coarctation of a high-positioned right arch. Pediatr Radiol; 2007 Jun;37(6):584-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Right circumflex retro-oesophageal aortic arch with coarctation of a high-positioned right arch.
  • We present a rare case of right circumflex retro-oesophageal aortic arch with coarctation of a high-positioned right arch.
  • MR aortography revealed a right aortic arch that was high-positioned, tortuous and narrowed.
  • This right aortic arch crossed the midline behind the oesophagus and continued as a left-sided descending aorta.
  • The left common carotid and subclavian arteries arose from a large branching vascular structure that derived from the top of the left-sided descending aorta.
  • The right common carotid artery arose from the ascending aorta.
  • The proximal portion of the right common carotid artery showed very severe stenosis and poststenotic dilatation.
  • The right subclavian artery originated distal to the narrowed and tortuous segment of the aortic arch.
  • [MeSH-major] Aortic Arch Syndromes / diagnosis. Aortic Coarctation / diagnosis. Magnetic Resonance Angiography
  • [MeSH-minor] Diagnosis, Differential. Humans. Infant. Male

  • Genetic Alliance. consumer health - Aortic Coarctation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br Heart J. 1966 Nov;28(6):722-39 [5332779.001]
  • [Cites] AJR Am J Roentgenol. 2002 May;178(5):1269-74 [11959744.001]
  • [Cites] Ann Thorac Surg. 2001 Jun;71(6):2030-2 [11426795.001]
  • [Cites] AJR Am J Roentgenol. 2005 May;184(5):1634-9 [15855130.001]
  • [Cites] Ann Thorac Surg. 1999 Apr;67(4):1194-202 [10320289.001]
  • [Cites] Ann Thorac Surg. 2001 Aug;72(2):611-3 [11515912.001]
  • (PMID = 17404722.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


73. Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E: Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int; 2009 Aug;104(4):456-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma.
  • OBJECTIVE: To prospectively establish objective selection criteria for metastasectomy in patients with metastatic renal cell carcinoma (mRCC).
  • PATIENTS AND METHODS: Between 1991 and 1999, 38 patients with mRCC with responsive or stable disease after initial systemic therapy, and with potentially resectable disease, were enrolled.
  • RESULTS: Of the patients enrolled, 79% had stable disease after initial systemic therapy and 21% had a partial or complete response.
  • There was surgically no evidence of disease (sNED) in 76%.
  • Eight of 38 patients (21%) remained free of disease by the end of the study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / therapy. Kidney Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Chemotherapy, Adjuvant. Disease-Free Survival. Feasibility Studies. Female. Fluorouracil / administration & dosage. Humans. Interferon-alpha / administration & dosage. Interleukin-2 / administration & dosage. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Middle Aged. Neoplasm, Residual. Nephrectomy. Prospective Studies. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19338544.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Interleukin-2; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS696820; NLM/ PMC4464661
  •  go-up   go-down


74. Capitanio U, Perrotte P, Zini L, Jeldres C, Shariat SF, Isbarn H, Arjane P, Peloquin F, Pharand D, Montorsi F, Karakiewicz PI: Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma). BJU Int; 2009 Sep;104(6):795-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma).
  • OBJECTIVE: To examine the cancer-specific mortality (CSM) of patients with T4N0-2M0 renal cell carcinoma (RCC) treated with either nephrectomy (RN) or no surgery (NS).
  • PATIENTS AND METHODS: Of 43 143 patients with RCC identified in the Surveillance, Epidemiology and End Results database, 310 had tumours involving adjacent organs with no evidence of distant metastases (T4NanyM0) and had RN (246, 79.4%) or NS (64, 20.6%).
  • Kaplan-Meier analyses, Cox regression and competing-risks regression models were used to compare the effect of RN vs NS on CSS.
  • RESULTS: In patients with T4N0 disease the median survival benefit associated with RN vs NS was 42 months (48 vs 6 months, P < 0.001).
  • Conversely, the median survival in patients T4N1-2 was no different between RN and NS (9.3 vs 9.1 months, P = 0.9).
  • Multivariable analyses in T4N0 cases indicated a substantial survival disadvantage for patients having NS vs RN (hazard ratio 4.8, P < 0.001).
  • Conversely, in patients with N1-2 stages, the CSS was virtually the same for NS and RN (hazard ratio 0.9, P = 0.9).
  • Competing-risks regression models confirmed the benefit of RC in patients with T4N0 and the lack of benefit in those with T4N1-2 disease, after controlling for other-cause mortality.
  • CONCLUSION: Our data suggest a survival benefit in patients with T4N0 RCC treated with RC.
  • By contrast, RN seems to have no effect on survival in patients with evidence of nodal metastases.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Nephrectomy / methods


75. Batista RR, Marchiori E, Takayassu TC, Cabral FC, Cabral RF, Zanetti G: Sternal metastasis as an initial presentation of renal cell carcinoma: a case report. Cases J; 2009;2:9045
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sternal metastasis as an initial presentation of renal cell carcinoma: a case report.
  • Renal cell carcinoma accounts for 85% of all solid renal tumors in adults.
  • We report here a case of solitary bone sternal metastasis as an initial presentation of clear-cell renal cell carcinoma in a 56-year-old woman.
  • The prognosis for patients with metastasized renal cell carcinoma is poor; treatment of metastasis is usually palliative and designed to provide comfort and pain relief.
  • Palliative nephrectomy may be considered for control of symptoms.
  • Radical nephrectomy associated with metastatic bone tumor resection is being tested to improve functional status and survival, especially when metastasis involves supporting bones.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2008 Oct;191(4):1220-32 [18806169.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2530-40 [10561319.001]
  • [Cites] Radiographics. 2007 Nov-Dec;27(6):1801-7 [18025518.001]
  • [Cites] AJR Am J Roentgenol. 2007 Aug;189(2):360-70 [17646462.001]
  • [Cites] BMC Gastroenterol. 2007;7:4 [17266757.001]
  • [Cites] Radiographics. 2006 Nov-Dec;26(6):1795-806; discussion 1806-10 [17102051.001]
  • [Cites] Radiographics. 2006 Jan-Feb;26(1):233-44 [16418254.001]
  • [Cites] Radiology. 2005 Jan;234(1):189-96 [15537838.001]
  • [Cites] Eur Urol. 1999;35(3):197-203 [10072620.001]
  • [Cites] Urol Clin North Am. 1994 Nov;21(4):601-24 [7974893.001]
  • [Cites] J Urol. 1986 Aug;136(2):376-9 [3735498.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] Urology. 1982 Aug;20(2):177-81 [7112827.001]
  • [Cites] JAMA. 2004 Jul 7;292(1):97-100 [15238597.001]
  • [Cites] AJR Am J Roentgenol. 2001 Sep;177(3):653-8 [11517065.001]
  • [Cites] J Med Case Rep. 2008;2:249 [18657269.001]
  • (PMID = 19918357.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2769487
  •  go-up   go-down


76. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM: Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol; 2009 Jul 10;27(20):3312-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
  • PURPOSE: Mature survival data and evaluation of vascular endothelial growth factor (VEGF) as a prognostic biomarker from the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) study in patients with renal cell carcinoma (RCC) are reported.
  • Baseline VEGF levels correlated with Eastern Cooperative Oncology Group performance status (P < .0001), Memorial Sloan-Kettering Cancer Center score (P < .0001), and PFS and OS in univariate (PFS, P = .0013; OS, P = .0009) and multivariate (PFS, P = .0231; OS, P = .0416) analyses of placebo patients and with short OS by multivariate analysis of patients receiving sorafenib (P = .0145).
  • CONCLUSION: Although an OS benefit was not seen on a primary intent-to-treat analysis, results of a secondary OS analysis censoring placebo patients demonstrated a survival advantage for those receiving sorafenib, suggesting an important cross-over effect.
  • VEGF levels are prognostic for PFS and OS in RCC.
  • The results of TARGET establish the efficacy and safety of sorafenib in advanced RCC.
  • [MeSH-major] Benzenesulfonates / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Cross-Over Studies. Diarrhea / chemically induced. Disease-Free Survival. Double-Blind Method. Fatigue / chemically induced. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Nausea / chemically induced. Niacinamide / analogs & derivatives. Phenylurea Compounds. Prognosis. Treatment Outcome. Vascular Endothelial Growth Factor A / blood


77. Boss A, Rempp H, Martirosian P, Clasen S, Schraml C, Stenzl A, Claussen CD, Schick F, Pereira PL: Wide-bore 1.5 Tesla MR imagers for guidance and monitoring of radiofrequency ablation of renal cell carcinoma: initial experience on feasibility. Eur Radiol; 2008 Jul;18(7):1449-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wide-bore 1.5 Tesla MR imagers for guidance and monitoring of radiofrequency ablation of renal cell carcinoma: initial experience on feasibility.
  • This study was conducted to test and demonstrate the feasibility of magnetic resonance (MR)-guided radiofrequency (RF) ablation of renal cell carcinoma (RCC) using a 1.5 T whole-body scanner equipped with a wide-bore superconductive magnet.
  • Two patients with contrast-enhancing renal masses were treated with multipolar RF ablation (Celon ProSurge).
  • Navigation and monitoring of RF ablation using the wide-bore system operating at 1.5 T were clearly improved compared to former experiences on a 0.2 T MR unit.
  • MR-guided RF ablation of RCC can safely be performed in a 1.5 T wide-bore scanner offering higher image quality, shorter acquisition time, and new monitoring modalities not feasible at 0.2 T.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Catheter Ablation. Kidney Neoplasms / surgery. Magnetic Resonance Imaging, Interventional / instrumentation

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2006 Mar;238(3):881-90 [16424244.001]
  • [Cites] Eur Radiol. 2006 Jun;16(6):1226-36 [16752153.001]
  • [Cites] J Vasc Interv Radiol. 2006 Mar;17(3):513-9 [16567676.001]
  • [Cites] J Magn Reson Imaging. 1998 Jan-Feb;8(1):110-4 [9500269.001]
  • [Cites] Eur Radiol. 2007 Sep;17(9):2253-61 [17375306.001]
  • [Cites] Magn Reson Med. 2004 Feb;51(2):353-61 [14755661.001]
  • [Cites] Cardiovasc Intervent Radiol. 2006 Sep-Oct;29(5):811-8 [16832595.001]
  • [Cites] Eur J Radiol. 2006 Aug;59(2):183-9 [16725292.001]
  • [Cites] Urology. 2006 Nov;68(5):983-7 [17095059.001]
  • [Cites] Invest Radiol. 2005 Sep;40(9):583-90 [16118551.001]
  • [Cites] AJR Am J Roentgenol. 2003 Jun;180(6):1509-13 [12760910.001]
  • [Cites] Radiology. 2004 Sep;232(3):835-45 [15333798.001]
  • [Cites] AJR Am J Roentgenol. 2003 Jun;180(6):1503-8 [12760909.001]
  • [Cites] Eur Radiol. 2007 Mar;17 (3):725-33 [17021704.001]
  • [Cites] Eur Radiol. 2005 May;15(5):960-7 [15756553.001]
  • [Cites] Eur Radiol. 2004 Aug;14(8):1449-55 [15150668.001]
  • (PMID = 18351355.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Spin Labels
  •  go-up   go-down


78. Peruzzi B, Bottaro DP: Beta-catenin signaling: linking renal cell carcinoma and polycystic kidney disease. Cell Cycle; 2006 Dec;5(24):2839-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta-catenin signaling: linking renal cell carcinoma and polycystic kidney disease.
  • Loss of von Hippel-Lindau (VHL) tumor suppressor gene function occurs in familial and most sporadic renal cell carcinoma (RCC), resulting in the aberrant expression of genes that control cell proliferation, invasion and angiogenesis.
  • The VHL gene product, pVHL, is part of an E3 ubiquitin ligase complex that targets hypoxia inducible factors for polyubiquitination and proteosomal degradation, implicating hypoxia response genes in RCC oncogenesis.
  • VHL loss also allows robust RCC cell invasiveness and morphogenesis in response to hepatocyte growth factor (HGF), an important regulator of kidney development and renal homeostasis.
  • Recent elucidation of the mechanism by which pVHL represses developmental HGF responses in adult kidney has identified another oncogenically relevant E3 ligase target: beta-catenin.
  • This discovery also further unifies recent insights into the molecular pathogenesis of polycystic kidney disease, where the identification of disease genes has revealed the integration of signaling pathways associated with primary cilia function and the regulation of cell growth and differentiation.
  • [MeSH-major] Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Polycystic Kidney Diseases / metabolism. Polycystic Kidney Diseases / pathology. Signal Transduction. beta Catenin / metabolism


79. Bolignano D, Medici MA, Coppolino G, Sciortino MT, Merlo FM, Campo S, Donato V, Venuti A, Sturiale A, Zaccaria D, Buemi A, Lacquaniti A, Buemi M: Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R). Urol Oncol; 2010 Nov-Dec;28(6):642-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R).
  • Using a culture model of CAKI-2 and A498 cancer cells, our study aimed to verify if renal carcinoma cells also express V2-R and whether receptor activation modulates their proliferation.
  • Immunofluorescence and RT-PCR showed that both CAKI-2 and A498 cells effectively synthesize and express the V2-R.
  • Administration of the vasopressin analogue DDAVP induced an evident growth in both CAKI-2 and A498 cell lines.
  • Our study shows for the first time that renal cancer may effectively synthesize and express the V2-R.
  • Furthermore, AVP exerts in vitro a proliferative effect by acting on this receptor, as the selective V2-R blockage is able to completely prevent the cellular growth.
  • A validation of these findings with in vivo models is required to ascertain if the eventual presence of V2-R could influence the aggressiveness of human renal neoplasias.
  • From this point of view, a new, interesting therapeutical application of V2-R antagonists in the treatment of renal cancer could also be proposed, similar to that successfully described in the treatment of autosomal polycystic kidney disease (ADPKD).
  • [MeSH-major] Kidney Neoplasms / metabolism. Receptors, Vasopressin / metabolism. Vasopressins / metabolism
  • [MeSH-minor] Aged. Antidiuretic Agents / pharmacology. Cell Line, Tumor. Cell Proliferation. Deamino Arginine Vasopressin / pharmacology. Fluorescent Antibody Technique. Humans. Male. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. VASOPRESSIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19217806.001).
  • [ISSN] 1873-2496
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidiuretic Agents; 0 / Receptors, Vasopressin; 11000-17-2 / Vasopressins; ENR1LLB0FP / Deamino Arginine Vasopressin
  •  go-up   go-down


80. Zimmermann R, Janetschek G: Complications of laparoscopic partial nephrectomy. World J Urol; 2008 Dec;26(6):531-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: LPN is still a challenging option for treatment of small renal cell cancer (RCC) and the technique is under development.
  • CONCLUSION: LPN is an additional but still challenging option for selected cases of RCC, which should be managed by the hands of experienced surgeons.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Laparoscopy / adverse effects. Nephrectomy / adverse effects. Postoperative Complications

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2005 May;173(5):1690-4 [15821559.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):469-7; discussion 475-6 [11792899.001]
  • [Cites] J Urol. 2003 Jul;170(1):64-8 [12796646.001]
  • [Cites] Eur Urol. 2007 Nov;52(5):1303-5 [17566640.001]
  • [Cites] Eur Urol. 2006 Nov;50(5):948-56; discussion 956-7 [16647188.001]
  • [Cites] J Urol. 2007 Jan;177(1):70-4; discussion 74 [17162003.001]
  • [Cites] Eur Urol. 2007 Feb;51(2):358-65 [16949197.001]
  • [Cites] J Urol. 2007 Jul;178(1):41-6 [17574056.001]
  • [Cites] J Urol. 2005 Jul;174(1):61-3 [15947578.001]
  • [Cites] J Urol. 2005 Jan;173(1):42-7 [15592022.001]
  • [Cites] J Endourol. 1993 Dec;7(6):521-6 [8124349.001]
  • [Cites] J Urol. 2005 Sep;174(3):841-5 [16093966.001]
  • [Cites] J Urol. 2005 Sep;174(3):855-8 [16093969.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):408-11 [12853787.001]
  • [Cites] J Urol. 2000 Feb;163(2):442-5 [10647650.001]
  • [Cites] Urology. 2005 Mar;65(3):463-6 [15780356.001]
  • [Cites] Eur Urol. 2000 Aug;38(2):131-8 [10895002.001]
  • [Cites] Urology. 2005 Nov;66(5):976-80 [16286106.001]
  • [Cites] BJU Int. 2005 Oct;96(6):811-4 [16153207.001]
  • [Cites] Eur Urol. 2008 Apr;53(4):732-42; discussion 742-3 [18222599.001]
  • [Cites] Clin Radiol. 2007 Nov;62(11):1104-9 [17920871.001]
  • [Cites] Eur Urol. 2007 Oct;52(4):1164-9 [17433532.001]
  • [Cites] J Urol. 2002 Jan;167(1):61-4 [11743276.001]
  • [Cites] J Urol. 2000 Mar;163(3):730-6 [10687966.001]
  • [Cites] Urology. 2002 Jun;59(6):816-20 [12031359.001]
  • [Cites] Mayo Clin Proc. 2000 Dec;75(12):1236-42 [11126830.001]
  • [Cites] Prog Urol. 2003 Feb;13(1):14-22 [12703349.001]
  • [Cites] J Urol. 2007 Feb;177(2):580-5 [17222637.001]
  • [Cites] J Urol. 2004 Jan;171(1):130-4 [14665860.001]
  • [Cites] J Urol. 2005 Dec;174(6):2256-9 [16280793.001]
  • [Cites] Eur Urol. 2007 Sep;52(3):798-803 [17329015.001]
  • [Cites] J Urol. 2007 Jun;177(6):2067-73; discussion 2073 [17509287.001]
  • [Cites] Eur Urol. 2005 Apr;47(4):488-93; discussion 493 [15774247.001]
  • (PMID = 18846378.001).
  • [ISSN] 0724-4983
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 33
  •  go-up   go-down


81. Blom JH, van Poppel H, Maréchal JM, Jacqmin D, Schröder FH, de Prijck L, Sylvester R, EORTC Genitourinary Tract Cancer Group: Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol; 2009 Jan;55(1):28-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881.
  • BACKGROUND: Until now the therapeutic value of lymphadenectomy for renal-cell carcinoma has remained controversial.
  • OBJECTIVE: To assess whether a complete lymph-node dissection in conjunction with a radical nephrectomy for renal-cell cancer is more effective than a radical nephrectomy alone.
  • DESIGN, SETTING, AND PARTICIPANTS: In 1988, the European Organization for Research and Treatment of Cancer (EORTC) Genitourinary Group started a randomized phase 3 trial comparing radical nephrectomy with a complete lymphadenectomy to radical nephrectomy alone.
  • After the renal-cell carcinoma was judged to be N0M0 and resectable, patients were randomly selected prior to surgery to undergo either a radical nephrectomy with a complete lymph-node dissection or to undergo a radical nephrectomy alone.
  • Postoperatively all patients were followed for progression of disease and mortality.
  • The study revealed no significant differences in overall survival, time to progression of disease, or progression-free survival between the two study groups.
  • CONCLUSIONS: This study shows that, after proper preoperative staging, the incidence of unsuspected lymph-node metastases is low (4.0%) and that, notwithstanding a possible relationship to this low incidence rate, no survival advantage of a complete lymph-node dissection in conjunction with a radical nephrectomy could be demonstrated.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Lymph Node Excision. Nephrectomy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2009 Jan;55(1):35-7 [18848383.001]
  • (PMID = 18848382.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 3U10 CA11488-18S1; United States / NCI NIH HHS / CA / 5U10 CA11488-38
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


82. Maubec E, Chaudru V, Mohamdi H, Grange F, Patard JJ, Dalle S, Crickx B, Paillerets BB, Demenais F, Avril MF: Characteristics of the coexistence of melanoma and renal cell carcinoma. Cancer; 2010 Dec 15;116(24):5716-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of the coexistence of melanoma and renal cell carcinoma.
  • BACKGROUND: Patients with melanoma (MM) have an increased risk of kidney cancer, and there is an excess risk of MM among patients with renal cell carcinoma (RCC).
  • The objective of the current study was to analyze a series of 42 patients with both MM and RCC to identify clinical and pathologic features as well as risk factors of this association.
  • METHODS: Clinical and pathologic characteristics of 42 patients who developed both MM and RCC (the MM + RCC series) were compared with 2 published series in each cancer alone: a series of 293 patients with MM (MM series) and a series of 1527 patients with RCC (RCC series).
  • RESULTS: RCC was diagnosed concomitantly or after MM in 83% of patients in the MM + RCC series.
  • Those patients displayed a high proportion of asymptomatic RCC at diagnosis (70%) and a higher frequency of stage I tumors (61%) than patients in the RCC series.
  • Compared with the MM series, patients in the MM + RCC series more often were men, had a higher frequency of blond/red hair, had poor tanning ability, and had a higher number of nevi.
  • In addition, patients in the MM + RCC series had a high aggregation of other malignancies (mainly skin cancers) and a significantly higher frequency of family history of MM (P = .005).
  • Only 2 cyclin-dependent kinase 2A gene (CDKN2A) germline mutations were identified among patients in the MM + RCC series who also were members of MM-prone families.
  • CONCLUSIONS: The high aggregation of cancers among patients in the MM + RCC series and the familial clustering of MM argued for a genetic predisposition that may be partly independent of CDKN2A.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Melanoma / diagnosis. Neoplasms, Multiple Primary / diagnosis
  • [MeSH-minor] Adult. Aged. Cyclin-Dependent Kinase 4. Family Health. Female. Genes, p16. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Risk Factors. Skin Neoplasms / diagnosis. Skin Neoplasms / genetics


83. Kroeger N, Gajda M, Zanow J, Petersen I, Settmacher U, Wunderlich H, Steiner T: Downsizing a tumor thrombus of advanced renal cell carcinoma with neoadjuvant systemic therapy and resulting histopathological effects. Urol Int; 2010;84(4):479-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downsizing a tumor thrombus of advanced renal cell carcinoma with neoadjuvant systemic therapy and resulting histopathological effects.
  • BACKGROUND: We report a treatment option in surgical therapy of locally advanced renal cell carcinoma (RCC).
  • METHOD: A 63-year-old patient with locally advanced RCC including an atrial thrombus underwent 2 cycles of neoadjuvant therapy (Sutent 50 mg daily for 4 weeks followed by 2 weeks off) and then tumor surgery.
  • Primary surgical therapy had to be delayed because of suspected bronchial carcinoma and additional diagnostics.
  • After neoadjuvant therapy to downsize the tumor thrombus and exclusion of any additional malignant tumors, operation was done via abdominal access; no sternotomy was necessary.
  • RESULTS: Histopathological examinations of the primary tumor after tyrosine kinase inhibitor therapy were evaluated and compared to tumor biopsy material taken before therapy.
  • CONCLUSION: Neoadjuvant therapy with Sutent may represent a favorable treatment option in cases of locally advanced clear-cell RCC with extended tumor thrombus.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Renal Cell / therapy. Indoles / administration & dosage. Kidney Neoplasms / therapy. Neoplastic Cells, Circulating / drug effects. Pyrroles / administration & dosage. Thrombectomy. Vena Cava, Inferior / surgery. Venous Thrombosis / therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 S. Karger AG, Basel.
  • (PMID = 20299776.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down


84. Barocas DA, Rabbani F, Scherr DS, Vaughan ED Jr: A population-based study of renal cell carcinoma and prostate cancer in the same patients. BJU Int; 2006 Jan;97(1):33-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A population-based study of renal cell carcinoma and prostate cancer in the same patients.
  • OBJECTIVE: To investigate the incidence of prostate cancer in men with renal cell carcinoma (RCC) and the incidence of RCC in men with prostate cancer.
  • METHODS: We evaluated the database of the Surveillance, Epidemiology and End Results Program of the National Cancer Institute from 1973 to 1996, to calculate the incidence of RCC in men with prostate cancer and the incidence of prostate cancer in men with RCC.
  • The standardized incidence ratio (SIR, observed/expected) was calculated for each of the scenarios of interest, as well as for RCC and prostate cancer in men with other common malignancies.
  • Lung/bronchus cancer, colon/rectal cancer, and non-Hodgkin lymphoma were selected for the control scenarios because they are the most common non-urological cancers among men in the USA.
  • RESULTS: There was a higher incidence of RCC in men with prostate cancer (SIR 1.25, P < 0.01).
  • RCC incidence was also higher in men with each of the other malignancies.
  • Prostate cancer incidence was higher in men with RCC (SIR 1.42, P < 0.001), but was not significantly elevated for any of the control scenarios.
  • CONCLUSIONS: The incidence of RCC is higher in men with each of the index cancers, whereas that for prostate cancer was higher only in men with RCC.
  • A common aetiological factor is possible.
  • Serial imaging might increase the detection of RCC among patients with a variety of index malignancies.
  • Patients with RCC who are followed by a urologist might be screened more rigorously for prostate cancer than patients with other primary malignancies, leading to increased detection in these men.
  • [MeSH-major] Carcinoma, Renal Cell / epidemiology. Kidney Neoplasms / epidemiology. Neoplasms, Multiple Primary / epidemiology. Prostatic Neoplasms / epidemiology


85. Blanco Díez A, Fernández Rosado E, Suárez Pascual G, Rodríguez Gómez I, Ruibal Moldes ML, Novás Castro S, Gómez Veiga F, Alvarez Castelo L, Barbagelata López A, Ponce Díaz-Reixa J, González Martín M: [Role of nephrectomy in metastatic renal cell carcinoma. Experience of the Department of Urology Juan Canalejo Hospital]. Actas Urol Esp; 2005 Feb;29(2):190-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of nephrectomy in metastatic renal cell carcinoma. Experience of the Department of Urology Juan Canalejo Hospital].
  • [Transliterated title] Papel de la nefrectomía en el adenocarcinoma renal metastático: experiencia del Servicio de Urología del Hospital Juan Canalejo.
  • OBJECTIVES: We expose our experience in nephrectomy in metastatic renal cell carcinoma, and also show complications, evolution and survival of these patients.
  • MATERIAL AND METHODS: We performe a retrospective review of renal cell carcinoma treated at our service in the period between January 1st 1991 and December 31st 2002.
  • CONCLUSIONS: In those patients with good performance status this approach does not represent more morbility nor mortality than in non-metastatic patients, and that is a cornerstone in their management.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Nephrectomy / mortality

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15881918.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


86. Nese N, Paner GP, Mallin K, Ritchey J, Stewart A, Amin MB: Renal cell carcinoma: assessment of key pathologic prognostic parameters and patient characteristics in 47,909 cases using the National Cancer Data Base. Ann Diagn Pathol; 2009 Feb;13(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma: assessment of key pathologic prognostic parameters and patient characteristics in 47,909 cases using the National Cancer Data Base.
  • On the basis of the National Cancer Data Base (NCDB), we describe the disease characteristics and use of conventional prognostic parameters in a hospital-based cohort of pathologically confirmed renal cell carcinomas (RCCs).
  • Between 1993 and 1998, the NCDB obtained 149 424 cases of kidney (and renal pelvis) cancers from registries all over the United States.
  • This database was queried for 47 909 histologically specified RCCs.
  • Renal cell carcinoma was more common in men (male-female ratio = 1.6:1).
  • Most (66.6%) were organ-confined (stage I/II) at the time of diagnosis.
  • The mean tumor size was 6.49 cm.
  • The 5-year observed survival of RCC was 62.9% for male and 68.1% for female and was 81.0% for younger than 40 years old and 64.2% for older than 40 years old.
  • The 5-year observed survival of RCC patients by the fifth edition 1997 American Joint Committee on Cancer TNM staging were stages I, 77.8%; II, 72.8%; III, 55.0%; and IV, 16.9%, demonstrating a dramatic decline in patient survival at stage IV.
  • By reported pathologic grade, significant stratification was achieved in the observed survival for RCC overall irrespective of histologic subtypes (grade 1, 77.8%; 2, 69.6%; 3, 48.8%; and 4, 35.3% 5-year observed survival).
  • These large NCDB data in RCC confirm the importance of pathologic evaluation of traditional prognostic parameters of stage and grade in RCC and is a powerful resource in defining cancer patient characteristics and analysis of prognostic variables that helps influence future cancer care planning and resource allocation.
  • [MeSH-major] Carcinoma, Renal Cell / mortality. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / mortality. Kidney Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cohort Studies. Databases, Factual. Disease-Free Survival. Female. Humans. Infant. Male. Middle Aged. Neoplasm Staging. United States / epidemiology. Young Adult


87. Dash A, Vickers AJ, Schachter LR, Bach AM, Snyder ME, Russo P: Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. BJU Int; 2006 May;97(5):939-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm.
  • OBJECTIVE: To compare the outcomes of patients who had a elective partial nephrectomy (PN) or radical nephrectomy (RN) for clear cell renal cell carcinoma (RCC) of 4-7 cm.
  • PATIENTS AND METHODS: From March 1998 to July 2004, 45 and 151 patients underwent PN and RN, respectively, for clear cell RCC.
  • A multivariate Cox model was constructed for disease-free survival with adjustment for markers of disease severity, and a propensity-score approach used as a confirmatory analysis.
  • RESULTS: In the PN and RN cohorts the treatment failed in one and 20 patients, respectively; the median follow-up was 21 months.
  • The hazard ratio (95% confidence interval) for PN after adjusting for disease severity was 0.36 (0.05-2.82; P = 0.3).
  • CONCLUSIONS: Renal function was preserved after PN for 4-7 cm clear cell RCC tumours.
  • When comparing the outcomes of PN and RN it is important to consider the intended operation as an independent variable.
  • There was no clear evidence that PN was associated with worse cancer control, although a continued follow-up of this and other cohorts is warranted.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Nephrectomy / methods
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Male. Middle Aged. Multivariate Analysis. Treatment Outcome


88. Weber A, Kristiansen I, Johannsen M, Oelrich B, Scholmann K, Gunia S, May M, Meyer HA, Behnke S, Moch H, Kristiansen G: The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer. BMC Cancer; 2008;8:369
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer.
  • Whereas it is known that c-myc alterations play a completely different role in various carcinomas of the urogenital tract, the relevance of FBPs is unclear.
  • METHODS: FBP1, FBP3 and c-myc expression was studied in 105 renal cell, 95 prostate and 112 urinary bladder carcinomas by immunohistochemistry using tissue microarrays.
  • RESULTS: High rates of FBP1 and FBP3 expression were observed in all cancer types.
  • There was a concomitant up-regulation of FBP1 and FBP3 in renal cell and prostate carcinomas (p < 0.001 both).
  • C-myc expression was detectable in 21% of prostate, 30% of renal and 34% of urothelial carcinomas.
  • Interestingly, strong FBP1 and FBP3 expression was associated with c-myc up-regulation in clear cell renal cell carcinomas (p < 0.001 and 0.09 resp.
  • ), but not in bladder or prostate cancer.
  • CONCLUSION: The correlation between FBP1/FBP3, c-myc and high proliferation rate in renal cell carcinoma provides strong in vivo support for the suggested role of FBP1 and FBP3 as activators of c-myc.
  • The frequent up-regulation of FBP1 and FBP3 in urothelial and prostate carcinoma suggests that FBPs also have an important function in gene regulation of these tumors.
  • [MeSH-minor] Chi-Square Distribution. Humans. Immunohistochemistry. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology. Male. Middle Aged. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Statistics, Nonparametric. Tissue Array Analysis. Urinary Bladder Neoplasms / metabolism. Urinary Bladder Neoplasms / pathology


89. Zhang J, Chen Y, Li J, Zhang R, Wu Y, Zou L, Zhao T, Zhang X, Han J, Chen A, Wu Y: Renal tubular epithelial expression of the coinhibitory molecule B7-DC (programmed death-1 ligand). J Nephrol; 2006 Jul-Aug;19(4):429-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal tubular epithelial expression of the coinhibitory molecule B7-DC (programmed death-1 ligand).
  • BACKGROUND: Renal tubular epithelial cells (TECs) function as antigen-presenting cells because they constitutively express MHC class II molecules and have the ability to present peptide antigen to CD4+T cells.
  • However, the costimulatory signals provided by TECs for optimal T-cell activation have not been fully characterized.
  • Increasing recognition of the importance of B7 dendritic cells (B7-DC) in immunoregulation raises the question of whether B7-DC is expressed on TECs and is involved in regulating TEC function.
  • Immunohistochemistry was performed on human kidney biopsies.
  • Coculture experiments were performed to confirm the role of TEC-related B7-DC in regulating CD4+T-cell activation.
  • RESULTS: Data revealed that B7-DC is specifically expressed on TECs with inflammatory factor induced and diseased human kidney samples, including chronic glomerulonephritis, lupus nephritis, tubulointerstitial nephritis and renal cell carcinoma.
  • B7-DC was a strong inhibitor of CD4+T-cell activation, as assessed by increased cytokine (interferon-gamma and interleukin-2) production and enhanced levels of T-cell activation marker CD69 in the presence of its blocking antibody.
  • B7-DC is especially well expressed on TECs of diseased kidney samples and significantly down-regulates T-cell activation.
  • [MeSH-major] Antigens, CD80 / physiology. Dendritic Cells / physiology. Kidney Tubules / immunology
  • [MeSH-minor] Animals. Antigens, CD / physiology. Apoptosis Regulatory Proteins / physiology. CD4-Positive T-Lymphocytes / immunology. Cell Line. Epithelial Cells / immunology. Humans. Immunohistochemistry. Interferon-gamma / pharmacology. Lymphocyte Activation. Mice. Programmed Cell Death 1 Receptor

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17048200.001).
  • [ISSN] 1121-8428
  • [Journal-full-title] Journal of nephrology
  • [ISO-abbreviation] J. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD80; 0 / Apoptosis Regulatory Proteins; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


90. Gruber M, Simon MC: Hypoxia-inducible factors, hypoxia, and tumor angiogenesis. Curr Opin Hematol; 2006 May;13(3):169-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia-inducible factors, hypoxia, and tumor angiogenesis.
  • Hypoxia-inducible factor is activated not only by hypoxia but also as a consequence of genetic mutations in a variety of tumors.
  • RECENT FINDINGS: Deficiency of the tumor suppressor von Hippel-Lindau leads to constitutively active hypoxia-inducible factor and hypoxia-inducible factor target gene expression.
  • The specific functions of hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha during development and tumor growth remain incompletely understood.
  • Whereas hypoxia-inducible factor-2alpha seems to be the critical hypoxia factor in renal cell carcinoma, hypoxia-inducible factor-1alpha plays a significant role in the growth of tumors in other tissues.
  • Loss of von Hippel-Lindau is not sufficient for neoplastic transformation, suggesting that hypoxia-inducible factor does not act alone to cause tumors.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / metabolism. Cell Hypoxia. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Neoplasms / blood supply. Neoplasms / metabolism. Neovascularization, Pathologic / metabolism
  • [MeSH-minor] Animals. Humans. Mutation. Von Hippel-Lindau Tumor Suppressor Protein / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16567961.001).
  • [ISSN] 1065-6251
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / endothelial PAS domain-containing protein 1; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  • [Number-of-references] 41
  •  go-up   go-down


91. Huan C, Sashital D, Hailemariam T, Kelly ML, Roman CA: Renal carcinoma-associated transcription factors TFE3 and TFEB are leukemia inhibitory factor-responsive transcription activators of E-cadherin. J Biol Chem; 2005 Aug 26;280(34):30225-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal carcinoma-associated transcription factors TFE3 and TFEB are leukemia inhibitory factor-responsive transcription activators of E-cadherin.
  • Translocations of the genes encoding the related transcription factors TFE3 and TFEB are almost exclusively associated with a rare juvenile subset of renal cell carcinoma and lead to overexpression of TFE3 or TFEB protein sequences.
  • Here we identify TFE3 and TFEB as cell type-specific leukemia inhibitory factor-responsive activators of E-cadherin.
  • Overexpression of TFE3 or TFEB in 3T3 cells activated endogenous and reporter E-cadherin expression.
  • Conversely, endogenous TFE3 and/or TFEB was required for endogenous E-cadherin expression in primary mouse embryonic fibroblasts and human embryonic kidney cells.
  • Chromatin precipitation analyses and E-cadherin promoter reporter gene assays revealed that E-cadherin induction by TFE3 or TFEB was primarily or exclusively direct and mitogen-activated protein kinase-dependent in those cell types.
  • In mouse embryonic fibroblasts, TFE3 and TFEB activation of E-cadherin was responsive to leukemia inhibitory factor.
  • In 3T3 cells, TFE3 and TFEB expression also induced expression of Wilms' tumor-1, another E-cadherin activator.
  • In contrast, E-cadherin expression in model mouse and canine renal epithelial cell lines was indifferent to inhibition of endogenous TFE3 and/or TFEB and was reduced by TFE3 or TFEB overexpression.
  • These results reveal new cell type-specific activities of TFE3 and TFEB which may be affected by their mutation.
  • [MeSH-major] Cadherins / metabolism. Carcinoma / metabolism. DNA-Binding Proteins / physiology. Gene Expression Regulation, Developmental. Interleukin-6 / metabolism. Kidney Neoplasms / metabolism. Neoplasm Proteins / physiology. Transcription Factors / physiology. WT1 Proteins / metabolism
  • [MeSH-minor] Animals. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors. Blotting, Western. Cell Line. Chromatin / metabolism. Chromatin Immunoprecipitation. DNA, Complementary / metabolism. Dogs. Enzyme Activation. Epithelial Cells. Fibroblasts / metabolism. Genes, Reporter. Genetic Vectors. Humans. Immunoprecipitation. Kidney / metabolism. Leukemia Inhibitory Factor. Luciferases / metabolism. MAP Kinase Signaling System. Mice. Microscopy, Confocal. Mutation. NIH 3T3 Cells. Plasmids / metabolism. Promoter Regions, Genetic. Protein Binding. RNA Interference. Retroviridae / genetics. Retroviridae / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transcription, Genetic. Transfection

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994295.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R21 DK065011-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Cadherins; 0 / Chromatin; 0 / DNA, Complementary; 0 / DNA-Binding Proteins; 0 / Interleukin-6; 0 / LIF protein, human; 0 / Leukemia Inhibitory Factor; 0 / Lif protein, mouse; 0 / Neoplasm Proteins; 0 / TFE3 protein, human; 0 / TFEB protein, human; 0 / Tcfeb protein, mouse; 0 / Transcription Factors; 0 / WT1 Proteins; 136896-33-8 / Tcfe3 protein, mouse; EC 1.13.12.- / Luciferases
  •  go-up   go-down


92. Christensen JG: A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol; 2007 Sep;18 Suppl 10:x3-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.
  • Sunitinib malate is an oral, multitargeted tyrosine kinase inhibitor that targets both angiogenic pathways (i.e., vascular endothelial growth factor receptor and platelet-derived growth factor receptor) and direct pro-oncogenic pathways (e.g., stem-cell factor receptor and FMS-like tyrosine kinase-3).
  • Clinical trial results have demonstrated the therapeutic potential of this agent and have implicated sunitinib targets in the pathophysiology of malignancies such as renal cell carcinoma and gastrointestinal stromal tumour.
  • It also highlights the importance of the multiple pathways that may be involved in cancer progression and the importance of these pathways in selected malignancies.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17761721.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Indoles; 0 / Protein Kinase Inhibitors; 0 / Pyrroles; 0 / sunitinib; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Number-of-references] 54
  •  go-up   go-down


93. Liberati P, Mathieu O, Tariel E, Meria P, Mongiat-Artus P, Desgrandchamps F, Teillac P: [Renal cancer: what can we expect from emerging new technologies: radiofrequency and cryoablation?]. Ann Urol (Paris); 2006 Nov;40 Suppl 3:S72-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal cancer: what can we expect from emerging new technologies: radiofrequency and cryoablation?].
  • [Transliterated title] Cancer du rein. Qu'attendre des nouvelles technologies: radiofréquence et cryoablation?
  • Radiofrequency and cryoablation are both minimally invasive techniques applied to the treatment of renal cell carcinoma.
  • Indications mostly accepted as elective indication are the less than 4 cm in diameter exophytic tumors.
  • Radiofrequency and cryoablation can also be proposed in patients with solitary kidney, multiple bilateral tumors and patients with contraindication for surgical resection.
  • The radiofrequency parietal tract can be coagulated at the time of radiofrequency electrode withdrawal reducing the rare risk of parietal tumor dissemination.
  • Preliminary oncological results in exophytic small renal tumors are promising with only few complications.
  • A longer follow-up is however mandatory to better define the place of these two new technologies in the treatment of renal cancer.
  • [MeSH-major] Catheter Ablation. Cryosurgery. Kidney Neoplasms / surgery

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17366859.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 24
  •  go-up   go-down


94. Negoro H, Kawakita M, Koda Y: Renal artery pseudoaneurysm after laparoscopic partial nephrectomy for renal cell carcinoma in a solitary kidney. Int J Urol; 2005 Jul;12(7):683-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal artery pseudoaneurysm after laparoscopic partial nephrectomy for renal cell carcinoma in a solitary kidney.
  • Renal artery pseudoaneurysms are a well-documented complication following trauma or percutaneous urological procedures, but are rare after partial nephrectomy.
  • We present the case of a 34-year-old woman who, after undergoing a left nephrectomy in childhood due to Wilms' tumor, had a pseudoaneurysm in a solitary kidney after laparoscopic right partial nephrectomy with extraperitoneal approach for a renal cell carcinoma.
  • The segmental renal artery feeding the pseudoaneurysm was embolized with coils without significant loss of residual renal function.
  • [MeSH-major] Aneurysm, False / etiology. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Laparoscopy. Nephrectomy / adverse effects. Renal Artery
  • [MeSH-minor] Adult. Female. Humans. Wilms Tumor / surgery

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045563.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


95. Heinroth S, Bilkenroth U, Eckert AW, Maurer P: [Bone metastases in the maxilla as first manifestation of renal cell cancer. A case report]. Mund Kiefer Gesichtschir; 2006 Jan;10(1):42-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bone metastases in the maxilla as first manifestation of renal cell cancer. A case report].
  • In many cases finding the primary tumour is difficult because of its occult location.
  • CASE REPORT: We describe a 53-year-old female patient who suffered from a tumor in the oral cavity.
  • The first histological and clinical diagnosis revealed a granuloma pyogenicum.
  • Because of the delayed healing process another biopsy became necessary showing a metastasis of an unknown primary tumor.
  • Diagnostic procedures detected an adenocarcinoma of the left kidney with pelvic metastases.
  • CONCLUSION: The present case report demonstrates how difficult it can be to provide the right pathological diagnosis in biopsy material even regarding obvious malignancy.
  • Therefore thorough diagnostic efforts are indispensable to facilitate the causal treatment of an unknown primary tumor.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / diagnosis. Maxillary Neoplasms / secondary
  • [MeSH-minor] Biopsy, Fine-Needle. Bone Neoplasms / diagnosis. Bone Neoplasms / pathology. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Combined Modality Therapy. Diagnosis, Differential. Disease Progression. Female. Humans. Kidney / pathology. Maxilla / pathology. Middle Aged. Pelvic Neoplasms / diagnosis. Pelvic Neoplasms / pathology. Pelvic Neoplasms / secondary. Pelvic Neoplasms / therapy

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2005 Jun;41(9):1246-53 [15939260.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):577-82 [11304694.001]
  • [Cites] Br J Oral Maxillofac Surg. 1990 Jun;28(3):172-5 [2135656.001]
  • [Cites] J Periodontol. 1980 Jul;51(7):413-5 [6930482.001]
  • [Cites] Laryngorhinootologie. 1998 Sep;77(9):525-7 [9795932.001]
  • [Cites] Laryngoscope. 1998 Sep;108(9):1301-5 [9738745.001]
  • [Cites] Urologe A. 1989 Nov;28(6):355-8 [2690442.001]
  • [Cites] Laryngorhinootologie. 1996 Mar;75(3):171-4 [8652034.001]
  • [Cites] Laryngoscope. 2002 Sep;112(9):1598-602 [12352670.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Mar;122(3):464 [10699832.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1487-91 [7272969.001]
  • [Cites] Ultraschall Med. 1999 Oct;20(5):218-22 [10595393.001]
  • [Cites] Arch Esp Urol. 1989 May;42(4):365-6 [2782966.001]
  • (PMID = 16402238.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


96. Duque-Fisher CS, Casiano R, Vélez-Hoyos A, Londoño-Bustamente AF: [Metastasis to the sinonasal region]. Acta Otorrinolaringol Esp; 2009 Nov-Dec;60(6):428-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Depending on the affected anatomical area, patients might have symptoms similar to the ones presented with a primary tumour of the area.
  • In many occasions, only a biopsy will give a final diagnosis and provide the treating physician with a pathway to follow.
  • We present two patients with metastatic carcinoma to the sphenoid from the thyroid and pancreas and two patients with metastatic renal cell carcinoma to the left nasal vestibule.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma, Follicular / secondary. Carcinoma, Renal Cell / secondary. Endoscopy / methods. Kidney Neoplasms / pathology. Nasopharyngeal Neoplasms / secondary. Pancreatic Neoplasms / pathology. Paranasal Sinus Neoplasms / secondary. Sphenoid Sinus / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19909719.001).
  • [ISSN] 1988-3013
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


97. Rosoff JS, Raman JD, Sosa RE, Del Pizzo JJ: Laparoscopic radical nephrectomy for renal masses 7 centimeters or larger. JSLS; 2009 Apr-Jun;13(2):148-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic radical nephrectomy for renal masses 7 centimeters or larger.
  • OBJECTIVE: To report our operative experience and oncologic outcomes for the laparoscopic management of large renal tumors.
  • Thirty patients with tumors >or=7cm and a pathologic diagnosis of renal cell carcinoma were included.
  • Of the 30 tumors, 18 were pathologic stage T2, 9 were stage T3a, 2 were stage T3b, and one was stage T4.
  • At a mean follow-up of 30 months (range, 10 to 70), 22 patients (73%) were alive without evidence of recurrence, and 5 patients (17%) were alive with disease.
  • One patient (3%) died of complications related to renal cell carcinoma, and 2 patients (7%) died from other causes.
  • Overall survival was 90%, cancer-specific survival was 97%, and recurrence-free survival was 80%.
  • CONCLUSION: Laparoscopic radical nephrectomy for large tumors is a technically challenging operation.
  • However, in experienced hands, it is a reasonable therapeutic option for the management of larger RCC neoplasms.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2001 Oct;58(4):517-20 [11597529.001]
  • [Cites] Urology. 2008 Jun;71(6):1149-54 [18313111.001]
  • [Cites] J Urol. 2002 Mar;167(3):1257-62 [11832709.001]
  • [Cites] Eur Urol. 2004 Apr;45(4):483-8; discussion 488-9 [15041113.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] N Engl J Med. 1991 May 9;324(19):1370-1 [1826761.001]
  • [Cites] J Urol. 2004 Dec;172(6 Pt 1):2172-6 [15538225.001]
  • [Cites] J Urol. 2005 Oct;174(4 Pt 1):1222-5 [16145374.001]
  • [Cites] Urol Oncol. 2005 Sep-Oct;23(5):323-7 [16144665.001]
  • [Cites] J Endourol. 2005 Sep;19(7):803-7 [16190832.001]
  • [Cites] Urology. 2006 Dec;68(6):1183-7 [17169642.001]
  • [Cites] J Urol. 2007 Mar;177(3):862-6 [17296361.001]
  • [Cites] J Endourol. 2007 Apr;21(4):408-10 [17451332.001]
  • [Cites] J Endourol. 2007 Apr;21(4):429-32 [17451337.001]
  • [Cites] Urology. 2008 Mar;71(3):421-4 [18342177.001]
  • [Cites] Cancer. 2001 Oct 1;92(7):1843-55 [11745257.001]
  • (PMID = 19660207.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3015927
  •  go-up   go-down


98. Sakura M, Kawakami S, Masuda H, Kobayashi T, Kageyama Y, Kihara K: Sequential bilateral minimum incision endoscopic radical nephrectomy in dialysis patients with bilateral renal cell carcinomas. Int J Urol; 2007 Dec;14(12):1109-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential bilateral minimum incision endoscopic radical nephrectomy in dialysis patients with bilateral renal cell carcinomas.
  • Since 1998, we have performed minimum incision endoscopic surgery (MIES) for renal cell carcinoma (RCC).
  • For seven dialysis patients with bilateral RCC, we have performed sequential bilateral MIES radical nephrectomy.
  • Although six of the seven patients had multiple complications in addition to chronic renal failure (CRF), bilateral kidneys were successfully removed by sequential MIES radical nephrectomy without major operative complication.
  • Sequential bilateral MIES radical nephrectomy, leaving the peritoneal cavity intact and without imposing circulatory stress caused by gas insufflation, is a feasible treatment for bilateral RCCs in dialysis patients.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Minimally Invasive Surgical Procedures / methods. Nephrectomy / methods. Renal Dialysis

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18036055.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


99. Dancer JY, Truong LD, Zhai Q, Shen SS: Expression of Galectin-3 in renal neoplasms: a diagnostic, possible prognostic marker. Arch Pathol Lab Med; 2010 Jan;134(1):90-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Galectin-3 in renal neoplasms: a diagnostic, possible prognostic marker.
  • CONTEXT: Galectin-3, a member of the lectin family, was shown to be expressed in normal distal tubular cells and in renal cell carcinomas (RCC).
  • However, its diagnostic and prognostic significance in RCC is as yet undefined.
  • OBJECTIVES: To describe the expression of Galectin-3 among different histologic subtypes of renal neoplasms and to determine their diagnostic and prognostic significances.
  • DESIGN: The expression of Galectin-3 was evaluated in 217 renal neoplasms by tissue microarray and immunohistochemistry with semiquantitative analysis.
  • RESULTS: Strong expression of Galectin-3 was observed in 92 of 217 of renal neoplasms (42.4%).
  • Although 22 of 23 oncocytomas (95.7%) and 19 of 21 chromophobe RCCs (90.5%) express Galectin-3, only 4 of 32 papillary RCCs (12.5%) and 47 of 137 clear cell RCCs (34.3%) express Galectin-3, suggesting that it may be used as a potential diagnostic marker.
  • Galectin-3 expression was seen in 55% of high-grade (Fuhrman nuclear grades 3 and 4) versus 21% low-grade (grades 1 and 2) clear cell RCCs (P < .001).
  • CONCLUSIONS: This study confirms that Galactin-3 is strongly overexpressed in renal cell neoplasms of distal tubular differentiation, that is, oncocytoma and chromophobe RCCs, suggesting it might be used as a possible differential diagnostic tool for renal cell neoplasm with oncocytic or granular cells.
  • Furthermore, we observed a strong association of overexpression of Galectin-3 and high nuclear grade in clear cell RCC.
  • These results also suggest a possible pivotal role for Galectin-3 in the differentiation and prognosis of clear cell RCC.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / metabolism. Galectin 3 / metabolism. Kidney Neoplasms / diagnosis. Kidney Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Humans. Kidney / metabolism. Kidney / pathology. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20073610.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


100. Ellis CL, Burroughs F, Michael CW, Li QK: Cytology of metastatic renal medullary carcinoma in pleural effusion: a study of two cases. Diagn Cytopathol; 2009 Nov;37(11):843-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytology of metastatic renal medullary carcinoma in pleural effusion: a study of two cases.
  • Renal medullary carcinoma (RMC) is a rare and aggressive malignant epithelial neoplasm of the kidney.
  • It almost exclusively affects children and young adults with a sickle cell trait or sickle cell disease.
  • The majority of RMC patients present with widely disseminated disease at the time of diagnosis.
  • Herein, we report two cases of young African-American patients with history of sickle cell trait, hematuria and renal mass, who present with malignant right pleural effusions.
  • The cytology of pleural effusion reveals predominantly clusters and individual tumor cells.
  • The tumor cells show high nuclear to cytoplasmic (NC) ratios and large nuclei with nuclear pleomorphism, nuclear grooves, and prominent single or multiple nucleoli.
  • Surgical specimens of renal mass and lymph node show features of RMC.
  • Metastatic RMC to the serous cavity is rare and may present a diagnostic dilemma since it may mimic a poorly differentiated adenocarcinoma or other high-grade malignant neoplasms.
  • RMC should be considered in the differential diagnosis in young patients with a renal mass, particularly in those with history of sickle cell trait or sickle cell disease.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Lung Neoplasms / secondary. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Immunohistochemistry. Sickle Cell Trait / complications

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526572.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement